Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~July 30,~~October 22, 2020, ~~45,047,262~~45,189,883 shares of the registrant’s common stock, $.01 par value, were outstanding.

Throughout this quarterly report on Form 10-Q (“this Report”), we refer to various trademarks, service marks and trade names that we use in our business. Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella ECP, Impella XR Sheath, Impella BTR, CVAD, STEMI DTU, ~~and~~ Automated Impella Controller and Abiomed Breethe OXY-1 System are pending trademarks of Abiomed, Inc. Other trademarks and service marks appearing in this Report are the property of their respective holders.

Throughout this Report, “ABIOMED, Inc.,” the “Company,” “we,” “us” and “our” refer to ABIOMED, Inc. and its consolidated subsidiaries.

We make available, free of charge on our website located at www.abiomed.com, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports, as soon as reasonably practicable after filing such reports with or furnishing such reports to the U.S. Securities and Exchange Commission (“SEC”). We also use our website for the distribution of Company information. The information we post on our website may be deemed to be material information. Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. The contents of our website are not incorporated by reference into this Report.

	June 30, 2020			March 31, 2020			September 30, 2020			March 31, 2020
ASSETS
Current assets:
Cash and cash equivalents	$	214,827		$	192,341		$	202,241		$	192,341
Short-term marketable securities		212,536			250,775			330,843			250,775
Accounts receivable, net		82,084			84,650			80,909			84,650
Inventories		89,284			90,088			83,209			90,088
Prepaid expenses and other current assets		20,958			18,009			19,419			18,009
Total current assets		619,689			635,863			716,621			635,863
Long-term marketable securities		169,668			207,795			202,613			207,795
Property and equipment, net		170,346			164,931			175,582			164,931
Goodwill		76,783			31,969			78,122			31,969
In-process research and development		42,223			14,913			42,895			14,913
Long-term deferred tax assets, net		30,875			43,336
Deferred tax assets								29,547			43,336
Other assets		139,928			117,655			82,594			117,655
Total assets	$	1,249,512		$	1,216,462		$	1,327,974		$	1,216,462
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	27,747		$	32,774		$	21,734		$	32,774
Accrued expenses		58,431			75,107			57,227			75,107
Deferred revenue		19,903			19,147			21,314			19,147
Other current liabilities		4,298			4,857			4,938			4,857
Total current liabilities		110,379			131,885			105,213			131,885
Contingent consideration		23,701			9,000			24,417			9,000
Long-term deferred tax liabilities		4,204			806
Deferred tax liabilities								4,251			806
Other long-term liabilities		9,380			9,305			11,684			9,305
Total liabilities		147,664			150,996			145,565			150,996
Commitments and contingencies (Note 14)
Stockholders' equity:
Class B Preferred Stock, $.01 par value		—			—			—			—
Authorized - 1,000,000 shares; Issued and outstanding - NaN
Authorized - 1,000,000 shares; Issued and outstanding - 0ne
Common stock, $.01 par value		450			451			452			451
Authorized - 100,000,000 shares; Issued - 47,698,298 shares at June 30, 2020 and 47,542,061 shares at March 31, 2020
Outstanding - 45,044,760 shares at June 30, 2020 and 45,008,687 shares at March 31, 2020
Authorized - 100,000,000 shares; Issued - 47,847,023 shares at September 30, 2020 and 47,542,061 shares at March 31, 2020
Outstanding - 45,189,883 shares at September 30, 2020 and 45,008,687 shares at March 31, 2020
Additional paid in capital		749,440			739,133			767,527			739,133
Retained earnings		647,070			602,482			709,283			602,482
Treasury stock at cost - 2,653,538 shares at June 30, 2020 and 2,533,374 shares at March 31, 2020		(286,577	)		(265,411	)
Treasury stock at cost - 2,657,140 shares at September 30, 2020 and 2,533,374 shares at March 31, 2020								(287,654	)		(265,411	)
Accumulated other comprehensive loss		(8,535	)		(11,189	)		(7,199	)		(11,189	)
Total stockholders' equity		1,101,848			1,065,466			1,182,409			1,065,466
Total liabilities and stockholders' equity	$	1,249,512		$	1,216,462		$	1,327,974		$	1,216,462

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

	For the Three Months Ended June 30,				For the Three Months Ended September 30,					For the Six Months Ended September 30,
	2020		2019		2020		2019			2020		2019
Revenue	$	164,850	$	207,666	$	209,764	$	204,974		$	374,614	$	412,640
Costs and expenses:
Cost of revenue		35,983		37,073		38,736		34,867			74,719		71,940
Research and development		26,357		23,790		30,525		23,969			56,882		47,759
Selling, general and administrative		68,444		86,078		79,167		85,956			147,611		172,034
		130,784		146,941		148,428		144,792			279,212		291,733
Income from operations		34,066		60,725		61,336		60,182			95,402		120,907
Other income (expenses):
Other income (expense):
Investment income, net		2,397		3,049		1,822		2,932			4,219		5,981
Other income, net		24,613		39,364
Other income (expense), net						9,757		(45,756	)		34,370		(6,392	)
		27,010		42,413		11,579		(42,824	)		38,589		(411	)
Income before income taxes		61,076		103,138		72,915		17,358			133,991		120,496
Income tax provision		16,488		14,215		10,702		4,287			27,190		18,502
Net income	$	44,588	$	88,923	$	62,213	$	13,071		$	106,801	$	101,994

Basic net income per share	$	0.99	$	1.97	$	1.38	$	0.29		$	2.37	$	2.25
Basic weighted average shares outstanding		45,010		45,215		45,104		45,319			45,057		45,267

Diluted net income per share	$	0.98	$	1.93	$	1.36	$	0.28		$	2.34	$	2.22
Diluted weighted average shares outstanding		45,549		46,092		45,661		45,912			45,609		46,031

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

	For the Three Months Ended June 30,					For the Three Months Ended September 30,						For the Six Months Ended September 30,
	2020			2019		2020			2019			2020			2019
Net income	$	44,588		$	88,923	$	62,213		$	13,071		$	106,801		$	101,994
Other comprehensive income (loss):
Foreign currency translation gain		1,360			2,334
Unrealized loss on derivative instrument		(461	)		—
Net unrealized gains on marketable securities		1,755			600
Foreign currency translation gains (losses)							2,416			(5,716	)		3,776			(3,382	)
Unrealized losses on derivative instrument							(266	)		—			(726	)		—
Net unrealized (losses) gains on marketable securities							(814	)		(85	)		940			515
Other comprehensive income		2,654			2,934		1,336			(5,801	)		3,990			(2,867	)

Comprehensive income	$	47,242		$	91,857	$	63,549		$	7,270		$	110,791		$	99,127

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

	Common Stock						Treasury Stock					Additional Paid			Retained		Accumulated Other			Total Stockholders'			Common Stock						Treasury Stock					Additional Paid			Retained		Accumulated Other			Total Stockholders'
	Shares			Par value			Shares		Amount			in Capital			Earnings		Comprehensive Loss			Equity			Shares			Par value			Shares		Amount			in Capital			Earnings		Comprehensive Loss			Equity
Balance, April 1, 2020		45,008,687		$	450			2,533,374	$	(265,411	)	$	739,133		$	602,482	$	(11,189	)	$	1,065,466			45,008,687		$	451			2,533,374	$	(265,411	)	$	739,133		$	602,482	$	(11,189	)	$	1,065,466
Restricted stock units issued		124,749			1			—		—			(1	)		—		—			—			124,749			1			—		—			(1	)		—		—			—
Stock options exercised		31,488			—			—		—			1,010			—		—			1,010			31,488			—			—		—			1,010			—		—			1,010
Return of common stock to pay withholding taxes on restricted stock		(52,515	)		—			52,515		(9,857	)		—			—		—			(9,857	)		(52,515	)		—			52,515		(9,857	)		—			—		—			(9,857	)
Stock compensation expense		—			—			—		—			9,298			—		—			9,298			—			—			—		—			9,298			—		—			9,298
Stock repurchase program		(67,649	)		(1	)		67,649		(11,309	)		—			—		—			(11,310	)		(67,649	)		(1	)		67,649		(11,309	)		—			—		—			(11,310	)
Other comprehensive income		—			—			—		—			—			—		2,654			2,654			—			—			—		—			—			—		2,654			2,654
Net income		—			—			—		—			—			44,588		—			44,588			—			—			—		—			—			44,588		—			44,588
Balance, June 30, 2020		45,044,760		$	450			2,653,538	$	(286,577	)	$	749,440		$	647,070	$	(8,535	)	$	1,101,848			45,044,760		$	450			2,653,538	$	(286,577	)	$	749,440		$	647,070	$	(8,535	)	$	1,101,848
Restricted stock units issued																								11,554			—			—		—			—			—		—			—
Stock options exercised																								121,066			1			—		—			4,544			—		—			4,545
Return of common stock to pay withholding taxes on restricted stock																								(3,602	)		—			3,602		(1,077	)		—			—		—			(1,077	)
Stock issued under employee stock purchase plan																								16,105			1			—		—			1,978			—		—			1,979
Stock compensation expense																								—			—			—		—			11,565			—		—			11,565
Other comprehensive income																								—			—			—		—			—			—		1,336			1,336
Net income																								—			—			—		—			—			62,213		—			62,213
Balance, September 30, 2020																								45,189,883		$	452			2,657,140	$	(287,654	)	$	767,527		$	709,283	$	(7,199	)	$	1,182,409

	Common Stock						Treasury Stock					Additional Paid			Retained		Accumulated Other			Total Stockholders'			Common Stock						Treasury Stock					Additional Paid			Retained		Accumulated Other			Total Stockholders'
	Shares			Par value			Shares		Amount			in Capital			Earnings		Comprehensive Loss			Equity			Shares			Par value			Shares		Amount			in Capital			Earnings		Comprehensive Loss			Equity
Balance, April 1, 2019		45,122,985		$	451			1,903,241	$	(138,852	)	$	690,507		$	399,473	$	(14,689	)	$	936,890			45,122,985		$	451			1,903,241	$	(138,852	)	$	690,507		$	399,473	$	(14,689	)	$	936,890
Restricted stock units issued		373,430			4			—		—			(4	)		—		—			—			373,430			4			—		—			(4	)		—		—			—
Stock options exercised		36,289			1			—		—			1,260			—		—			1,261			36,289			1			—		—			1,260			—		—			1,261
Return of common stock to pay withholding taxes on restricted stock		(158,426	)		(2	)		158,426		(40,534	)		—			—		—			(40,536	)		(158,426	)		(2	)		158,426		(40,534	)		—			—		—			(40,536	)
Stock compensation expense		—			—			—		—			13,121			—		—			13,121			—			—			—		—			13,121			—		—			13,121
Other comprehensive income		—			—			—		—			—			—		2,934			2,934			—			—			—		—			—			—		2,934			2,934
Net income		—			—			—		—			—			88,923		—			88,923			—			—			—		—			—			88,923		—			88,923
Balance, June 30, 2019		45,374,278			454			2,061,667		(179,386	)		704,884			488,396		(11,755	)		1,002,593			45,374,278		$	454			2,061,667	$	(179,386	)	$	704,884		$	488,396	$	(11,755	)	$	1,002,593
Restricted stock units issued																								12,039			—			—		—			—			—		—			—
Stock options exercised																								21,268			—			—		—			1,445			—		—			1,445
Return of common stock to pay withholding taxes on restricted stock																								(3,363	)		—			3,363		(668	)		—			—		—			(668	)
Stock issued under employee stock purchase plan																								15,659			—			—		—			2,368			—		—			2,368
Stock compensation expense																								—			—			—		—			13,323			—		—			13,323
Stock repurchase program																								(180,929	)		(2	)		180,929		(34,872	)		—			—		—			(34,874	)
Other comprehensive loss																								—			—			—		—			—			—		(5,801	)		(5,801	)
Net income																								—			—			—		—			—			13,071		—			13,071
Balance, September 30, 2019																								45,238,952		$	452			2,245,959	$	(214,926	)	$	722,020		$	501,467	$	(17,556	)	$	991,457

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

	For the Three Months Ended June 30,						For the Six Months Ended September 30,
	2020			2019			2020			2019
Operating activities:
Net income	$	44,588		$	88,923		$	106,801		$	101,994
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		5,480			4,365			11,137			9,052
Bad debt expense		(277	)		(21	)
Bad debt (recoveries) expense								(373	)		152
Stock-based compensation		9,298			13,121			20,863			26,445
Write-down of inventory and other		1,717			1,259			3,122			2,157
Accretion on marketable securities		94			(1,306	)		473			(2,276	)
Change in fair value of other investments		(23,823	)		(39,654	)		(33,872	)		5,943
Deferred tax provision		12,946			10,776			14,187			10,195
Change in fair value of contingent consideration		801			356			2,117			661
Other non-cash operating activities		970			1,003			2,008			2,177
Changes in assets and liabilities:
Accounts receivable		3,014			4,801			4,767			(3,828	)
Inventories		(211	)		(7,239	)		6,071			(12,204	)
Prepaid expenses and other assets		485			(3,417	)		1,744			(4,077	)
Accounts payable		(4,458	)		(1,463	)		(10,128	)		781
Accrued expenses and other liabilities		(19,584	)		(6,643	)		(21,988	)		(1,268	)
Deferred revenue		719			(233	)		2,039			2,983
Net cash provided by operating activities		31,759			64,628			108,968			138,887
Investing activities:
Purchases of marketable securities		(62,066	)		(124,067	)		(294,558	)		(268,485	)
Proceeds from the sale and maturity of marketable securities and other		139,813			93,180			220,197			262,881
Purchases of other investments and intangible assets		(2,000	)		(2,800	)		(3,100	)		(7,800	)
Acquisition of Breethe Inc., net of cash acquired		(51,947	)		—			(52,183	)		—
Proceeds from sales of Shockwave Medical securities								67,882			—
Purchases of property and equipment		(10,044	)		(12,250	)		(19,552	)		(24,607	)
Net cash provided by (used for) investing activities		13,756			(45,937	)
Net cash used for investing activities								(81,314	)		(38,011	)
Financing activities:
Proceeds from the exercise of stock options		1,010			1,260			5,555			2,706
Taxes paid related to net share settlement upon vesting of stock awards		(9,857	)		(40,536	)		(10,934	)		(41,206	)
Repurchase of common stock		(11,310	)		—			(11,310	)		(34,873	)
Proceeds from the issuance of stock under employee stock purchase plan								1,978			2,368
Net cash used for financing activities		(20,157	)		(39,276	)		(14,711	)		(71,005	)
Effect of exchange rate changes on cash		(2,872	)		612
Net increase (decrease) in cash and cash equivalents		22,486			(19,973	)
Effect of exchange rate changes on cash and cash equivalents								(3,043	)		(613	)
Net increase in cash and cash equivalents								9,900			29,258
Cash and cash equivalents at beginning of period		192,341			121,021			192,341			121,021
Cash and cash equivalents at end of period	$	214,827		$	101,048		$	202,241		$	150,279

Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	2,831		$	2,584		$	25,254		$	6,349
Supplemental disclosure of non-cash activities:
Contingent consideration related to the acquisition of Breethe, Inc.		13,900			—			13,300			—
Property and equipment in accounts payable and accrued expenses		2,044			3,619			1,244			3,825
Right-of-use assets obtained in exchange for lease liabilities		804			14,139			193			14,513

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

ABIOMED, Inc. (the “Company” or “ABIOMED”) is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company’s products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020 that has been filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments that are necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year or any other subsequent period. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from these estimates.

There have been no changes in the Company’s significant accounting policies for the three and six months ended ~~June~~September 30, 2020 as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020 that has been filed with the SEC.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from these estimates.

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the response to the pandemic is developing and information is rapidly evolving. Considerable uncertainty still surrounds the COVID-19 virus and its potential effects, and the extent of and effectiveness of responses taken on international, national and local levels. Measures taken to limit the impact of COVID-19, including shelter-in-place orders, social distancing measures, travel bans and restrictions, and business and government shutdowns, continue to create significant negative economic impacts on a global basis.

~~Due~~ The extent of the impact of the COVID-19 pandemic on the Company's business remains uncertain and difficult to ~~these impacts and measures,~~predict, as the Company has experienced, and may continue to experience, significant and unpredictable reductions in the demand for its products as healthcare customers divert medical resources and priorities towards the treatment of COVID-19. In addition, the Company’s customers may delay, cancel, or redirect planned purchases in order to focus resources on COVID-19 or in response to ~~economic disruption related~~the pandemic continues to ~~COVID-19.~~ evolve.

Beginning in mid-March 2020 and continuing into the first quarter of fiscal 2021, the Company experienced a significant decline in patient utilization in the U.S., Europe and Japan as healthcare systems diverted resources to meet the increasing demands of managing COVID-19. The Company also experienced temporary delays in clinical trial enrollment or encountered interruption or delays in the operations of FDA or other regulatory authorities due to the COVID-19 pandemic, which may impact review and approval timelines. The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on its customers, all of which are uncertain and cannot be predicted.

Impella procedure volumes have varied greatly since the end of March 2020 by geography, and even by hospital, as patients and their physicians managed through the COVID-19 pandemic. In the last few weeks of the fourth quarter of fiscal 2020, procedure volumes related to the Company’s Impella products dropped significantly. Worldwide Impella heart pump revenue was impacted by lower patient utilization in the first quarter of fiscal 2021 due to the impact of the COVID-19 pandemic on elective medical procedures, surgeries and fewer patients seeking treatment at hospitals. Total revenue for the three months ended June 30, 2020 decreased by $42.8 million, or 21%, to $164.9 million from $207.7 million for the three months ended June 30, 2019. The decrease in total revenue was due to lower utilization caused by the impact of COVID-19 on hospitals in the first quarter of fiscal 2021.

~~levels. The~~ Company’s business was most impacted in April 2020, in terms of the decline in patients and revenue from the shelter-in-place restrictions in a majority of countries and limitations on procedures in hospitals. The Company experienced sequential quarterly improvement globally ~~in May and June~~through the second quarter of fiscal 2021 as restrictions were lifted and limitations eased. In the ~~month~~second quarter of ~~June specifically,~~fiscal 2021, patient procedure volume trends have improved gradually as both demand for procedures and availability of healthcare resources improved during the ~~Company experienced year over year growth in both patients and revenue in U.S., Germany, and Japan.~~summer months.

While the Company currently expects to see sequential quarterly improvement in the remainder of fiscal 2021, the COVID-19 pandemic remains fluid and continues to evolve differently across various geographies. The Company believes it is likely to continue to experience variable impacts on its business based on some of the resurgence that is now occurring in cities across the globe. Given the uncertainty, the Company cannot reliably estimate the extent to which the COVID-19 pandemic may continue to impact patient utilization and revenues of its products in the second quarter of fiscal 2021 and beyond.globe.

The Company is closely monitoring the impact of COVID-19 on all aspects of its business and geographies, including the impact on its customers, employees, suppliers, vendors, business partners and distribution channels. The extent to which the COVID-19 global pandemic impacts the Company’s business, results of operations, and financial condition will depend on future developments, which are highly uncertain and are difficult to predict; these developments include, but are not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or address its impact, U.S. and foreign government actions to respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, the Company may continue to experience materially adverse impacts on its financial condition and results of operations. As of the date of issuance of these consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations is uncertain.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326).” This new standard requires financial instruments to be measured at amortized cost, and accounts receivables to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information, and reasonable and supportable forecasts, including estimates of prepayments. The Company adopted this standard in the first quarter of fiscal 2021 and it did not have a material impact on the Company’s consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other (Topic 350).” This new standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which required companies to estimate the implied fair value of goodwill and recognize an impairment charge by the amount in which the carrying value exceeds the implied fair value. Under the new guidance, if the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge will be recorded, even if the difference is attributable to the fair value of other assets in the reporting unit. The Company adopted this standard in the first quarter of fiscal 2021 and it did not have a material impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820).” This new standard modifies the disclosure requirements on fair value measurements, including the removal of disclosures of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. The guidance also adds certain disclosure requirements related to Level 3 fair value measurements. The Company adopted this standard in the first quarter of fiscal 2021 and it did not have a material impact on the Company’s consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740).” This amendment to the guidance on income taxes is intended to simplify the accounting for income taxes. The amendment eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. The amendment also clarifies existing guidance related to the evaluation of a step up in the tax basis of goodwill and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. ASU 2019-12 will become effective for the Company in fiscal 2022.

In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815),” an amendment clarifying the interaction between accounting standards related to equity securities, equity method investments, and certain derivative instruments. The guidance is effective for fiscal years beginning after December 15, 2020. ASU 2020-01 will become effective for the Company in fiscal 2022.

The Company acquired Breethe, Inc. (“Breethe”), a Maryland corporation on April 24, 2020. Breethe is engaged in research and development of a novel extracorporeal membrane oxygenation (“ECMO”) system that ~~the Company expects~~ will complement and expand its product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including ~~some~~ patients suffering from cardiogenic shock, or respiratory failure, such as ARDS, H1N1, or COVID-19. The Company acquired Breethe for $55.0 million in cash, with additional potential payouts up to a maximum of $55.0 million payable based on the achievement of certain technical, regulatory and commercial milestones.

The acquisition was accounted for as a business combination. The purchase price for the acquisition has been allocated to the assets acquired and liabilities assumed based on their estimated fair values. The purchase price allocation presented herein is

preliminary. The final purchase price allocation will be determined after completion of an analysis to determine the fair value of all assets acquired and liabilities assumed, but in no event later than one year following completion of the acquisition. Accordingly, the final acquisition accounting adjustments could differ materially from the preliminary amounts presented herein. Any increase or decrease in the fair value of the assets acquired and liabilities assumed, as compared to the information shown herein, could also change the portion of purchase price allocated to goodwill and could impact the operating results of the Company following the acquisition due to differences in purchase price allocation, depreciation and amortization related to some of these assets and liabilities.

	Total Acquisition Date Fair Value (in thousands)		Total Acquisition Date Fair Value (in thousands)
Cash and other considerations	$	57,351	$	57,850
Contingent consideration		13,900		13,300
Total consideration transferred	$	71,251	$	71,150

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed on ~~April 24, 2020,~~ the date of acquisition (in thousands):

Acquired assets:
Cash and cash equivalents	$	3,404	$	3,404
Property and equipment		744		744
Goodwill		44,149		44,048
In-process research and development		27,000		27,000
Other assets acquired		895		895
Total assets acquired		76,192		76,091
Liabilities assumed:
Accounts payable and other liabilities		1,562		1,562
Long-term deferred tax liabilities		3,379
Deferred tax liabilities				3,379

Net assets acquired	$	71,251	$	71,150

Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill is not expected to be deductible for income tax purposes.

In process research and development (“IPR&D”) is the estimated fair value of the Breethe ECMO technology which had not reached commercial technological feasibility nor had alternative future use at the time of the acquisition and is therefore considered IPR&D. The assigned values are allocated among the various IPR&D assets acquired.

Transaction costs such as legal, insurance and other costs related to the acquisition, aggregating approximately $0.9 million, have been expensed as incurred and are included in selling, general and administrative expenses in our condensed consolidated statements of operations.

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of dilutive common shares outstanding during the period. Diluted shares outstanding are calculated by adding to the weighted average shares outstanding any potential dilutive securities outstanding for the period. Potential dilutive securities include stock options, restricted stock units, performance-based stock awards and shares to be purchased under the Company’s employee stock purchase plan. The Company’s basic and diluted net income per share for the three and six months ended ~~June~~September 30, 2020 and 2019 were as follows (in thousands, except per share data):

	For the Three Months Ended June 30,				For the Three Months Ended September 30,				For the Six Months Ended September 30,
Basic Net Income Per Share		2020		2019		2020		2019		2020		2019
Net income	$	44,588	$	88,923	$	62,213	$	13,071	$	106,801	$	101,994

Weighted average shares – basic		45,010		45,215		45,104		45,319		45,057		45,267

Net income per share – basic	$	0.99	$	1.97	$	1.38	$	0.29	$	2.37	$	2.25

	For the Three Months Ended June 30,				For the Three Months Ended September 30,				For the Six Months Ended September 30,
Diluted Net Income Per Share		2020		2019		2020		2019		2020		2019
Net income	$	44,588		88,923	$	62,213		13,071		106,801		101,994

Weighted average shares – basic		45,010		45,215		45,104		45,319		45,057		45,267
Effect of dilutive securities		539		877		557		593		552		764
Weighted average shares – diluted		45,549		46,092		45,661		45,912		45,609		46,031

Net income per share – diluted	$	0.98	$	1.93	$	1.36	$	0.28	$	2.34	$	2.22

~~For~~Share-based compensation awards of approximately 0.1 million and 0.3 million shares for the three months ended ~~June~~September 30, 2020, and 2019, respectively, and approximately ~~249,000~~0.2 million and ~~117,200 shares of common stock underlying~~0.3 million for the six months ended September 30, 2020, and 2019, respectively, were outstanding ~~securities related to out-of-the-money stock options and performance-based awards where milestones were not met~~but were not included in the computation of diluted ~~earnings~~net income per share because ~~their inclusion~~the effect of including such shares would ~~be anti-dilutive.~~have been anti-dilutive or are contingently issuable upon meeting performance criteria in the periods presented.

The Company generates revenue primarily from the sale of Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella RP, Impella 5.5 and Impella AIC products. The Company also earns revenue from preventative maintenance service contracts and maintenance calls.

Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.

Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.

Service revenue is generally recognized over time as the services are rendered to the customer based on the extent of progress towards completion of the performance obligation. The Company recognizes service revenue over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer. Revenue generated from preventative maintenance calls is recognized at a point in time when the services are provided to the customer.

Revenue from the sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale and shipment of product or service provided has been incurred. The Company performs a review of each specific customer’s credit worthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers’ creditworthiness prospectively.

If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately.

The Company generally sells most of its products and services through a direct sales force in the U.S., Germany and Japan and through direct sales or ~~distribution agreements~~distributors in other international markets (e.g., certain other European markets, Canada, Latin America, and Asia-Pacific). Revenue is disaggregated from contracts between product revenue and service and other revenue and by geography, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors.

The following table disaggregates the Company’s revenue by products and services:

	For the Three Months Ended June 30,				For the Three Months Ended September 30,				For the Six Months Ended September 30,
		2020		2019		2020		2019		2020		2019
	(in $000's)				(in $000's)				(in $000's)
Impella product revenue	$	155,417	$	199,864	$	199,676	$	196,939	$	355,093	$	396,804
Service and other revenue		9,433		7,802		10,088		8,035		19,521		15,836
Total revenue	$	164,850	$	207,666	$	209,764	$	204,974	$	374,614	$	412,640

The following table disaggregates the Company’s revenue by geographical location:

	For the Three Months Ended June 30,				For the Three Months Ended September 30,				For the Six Months Ended September 30,
		2020		2019		2020		2019		2020		2019
	(in $000's)				(in $000's)				(in $000's)
U.S. revenue	$	134,725	$	175,486	$	172,147	$	172,015	$	306,872	$	347,500
International revenue		30,125		32,180		37,617		32,959		67,742		65,140
Total revenue	$	164,850	$	207,666	$	209,764	$	204,974	$	374,614	$	412,640

The Company estimates an allowance for future sales returns based on historical return experience, which requires judgment. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company estimates product return liabilities using the expected value method based on its historical sales information and other factors that it believes could significantly impact its expected returns, including product discontinuations, product recalls and expirations, of which it becomes aware. The Company’s cost of replacing defective products has not been material and is accounted for at the time of replacement. The Company’s returns reserve during the three and six months ended ~~June~~September 30, 2020 and 2019, were not material.

The Company provides certain customers with rebates and discounts that are defined in the Company’s contract arrangements with customers and are recorded as a reduction of revenue in the period the related ~~product~~ revenue is recognized, resulting in a reduction to revenue and the establishment of a liability, which are all included in accrued expenses in the accompanying consolidated balance ~~sheets.~~sheet. Rebates normally result from performance-based offers that are primarily based on attaining contractually specified sales volumes as well as product usage. Discounts are normally from early payment incentives. The Company estimates the amount of rebates and discounts based on an estimate of the third-party’s sales and the respective rebate or discount defined in the customer contractual arrangement. Revenue adjustments that relate to performance obligations satisfied in prior periods during the three and six months ended ~~June~~September 30, 2020 and 2019, were not material.

The Company’s deferred revenue balance was ~~$19.9~~$21.3 million and $19.1 million as of ~~June~~September 30, 2020 and March 31, 2020 respectively. The deferred revenue balance is due to the timing of product shipment and completion of recognizing revenue when the customer obtains control of the product, and additional preventative maintenance service contracts and the subsequent recognition of the contract ratably over the term of the service contract. During the three and six months ended ~~June~~September 30, 2020, ~~and 2019,~~ the Company recognized ~~$9.2~~$5.4 million and ~~$8.5~~$14.6 million of revenue that was included in the deferred revenue balance as of March 31, 2020, respectively. During the three and six months ended September 30, 2019, the Company recognized $4.0 million and $12.5 million of revenue that was included in the deferred revenue balance as of March 31, 2019, respectively.

The Company’s cash equivalents and marketable securities at ~~June~~September 30, 2020 and March 31, 2020 are invested in the following:

	Amortized		Gross Unrealized		Gross Unrealized			Fair Market		Amortized		Gross Unrealized		Gross Unrealized			Fair Market
	Cost		Gains		Losses			Value		Cost		Gains		Losses			Value
June 30, 2020:	(in $000's)
September 30, 2020										(in $000's)
Money market funds	$	130,012	$	—	$	—		$	130,012	$	104,305	$	—	$	—		$	104,305
Repurchase agreements		20,000		—		—			20,000		20,000		—		—			20,000
Total cash equivalents		150,012		—		—			150,012		124,305		—		—			124,305

Short-term U.S. Treasury mutual fund securities		42,180		227		—			42,407		75,505		85		(1	)		75,589
Short-term government-backed securities		39,921		210		—			40,131		85,360		105		(9	)		85,456
Short-term corporate debt securities		109,426		588		—			110,014		128,738		1,043		—			129,781
Short-term commercial paper		19,898		86		—			19,984		39,991		31		(5	)		40,017
Total short-term marketable securities		211,425		1,111		—			212,536		329,594		1,264		(15	)		330,843

Long-term U.S. Treasury mutual fund securities											10,246		2		—			10,248
Long-term government-backed securities		75,483		66		(5	)		75,544		141,378		164		(6	)		141,536
Long-term corporate debt securities		91,868		2,256		—			94,124		49,627		1,202		—			50,829
Total long-term marketable securities		167,351		2,322		(5	)		169,668		201,251		1,368		(6	)		202,613

	$	528,788	$	3,433	$	(5	)	$	532,216	$	655,150	$	2,632	$	(21	)	$	657,761

	Amortized		Gross Unrealized		Gross Unrealized			Fair Market
	Cost		Gains		Losses			Value
March 31, 2020:	(in $000's)
Money market funds	$	115,019	$	—	$	—		$	115,019
Repurchase agreements		20,000		—		—			20,000
Total cash equivalents		135,019		—		—			135,019

Short-term U.S. Treasury securities		42,236		412		—			42,648
Short-term government-backed securities		67,594		401		—			67,995
Short-term corporate debt securities		107,290		94		(83	)		107,301
Short-term commercial paper		32,757		74		—			32,831
Total short-term marketable securities		249,877		981		(83	)		250,775

Long-term government-backed securities		90,911		153		—			91,064
Long-term corporate debt securities		116,110		851		(230	)		116,731
Total long-term marketable securities		207,021		1,004		(230	)		207,795

	$	591,917	$	1,985	$	(313	)	$	593,589

In October 2019, the Company entered into an intercompany agreement in which it loaned 85.0 million Euro to Abiomed Europe GMBH, its German subsidiary. In conjunction with this intercompany loan agreement, the Company entered into a cross-currency swap agreement to convert a notional amount of 85.0 million Euro equivalent to $93.5 million denominated intercompany loan into U.S. dollars. The objective of this cross-currency swap is to hedge the variability of cash flows related to the forecasted interest and principal payments on the Euro denominated fixed rate loan against changes in the exchange rate between the U.S. dollar and the Euro. Under the terms of this cross-currency swap contract, which has been designated as a cash flow hedge, the Company will make interest payments in Euro and receive interest in U.S. dollars. Upon the maturity of this contract, the Company will pay the principal amount of the loan in Euro and receive U.S. dollars from the counterparty. The cross-currency swap is carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in accumulated other comprehensive income (loss).

The Company uses a foreign-exchange-related derivative instrument to manage its exposure related to changes in the exchange rate on its intercompany loan. The Company does not enter into derivative instruments for any purpose other than cash flow hedging.

The following table summarizes the terms of the cross-currency swap agreement as of ~~June~~September 30, 2020 (dollar amounts in thousands):

The following table presents the fair value of the Company’s derivative instrument as of ~~June~~September 30, 2020:

Derivatives designated as hedging instruments under ASC 815

Balance Sheet classification

Fair Value

Balance Sheet classification

Fair Value

Cross-currency swap

Other assets (long-term liabilities)

1,504

Other assets (long-term liabilities)

(2,860

)

The Company has structured its cross-currency swap agreement to be 100% effective and, as a result, there was no net impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of the cross-currency swap are designated as a hedging instrument that effectively offsets the variability of cash flows are reported in accumulated other comprehensive income (loss). These amounts subsequently are reclassified into the consolidated income statement in the same period in which the related hedged item affects earnings. The change of fair value of the cross-currency swap during the second quarter for fiscal year 2021 was mainly due to the appreciation of the Euro against the U.S. dollar.

For both the three and six months ended ~~June~~September 30, 2020, the Company recorded income of ~~$0.4~~$0.7 million, in other income, net, included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

Contingent consideration represents potential milestones that the Company may pay as additional consideration related to acquired businesses. The Company has contingent consideration potentially payable related to the acquisition of ECP Entwicklungsgesellschaft mbH ~~or ECP~~(“ECP”) in July 2014 and the acquisition of Breethe, Inc. in April 2020. The fair value of the contingent consideration at each reporting date is updated by reflecting the changes in fair value reflected within research and development expenses in the Company’s consolidated statement of operations. Significant increases or decreases in any valuation assumptions, including probabilities of success or changes in expected timelines for achievement of any of these milestones, could result in a significantly higher or lower fair value of the contingent consideration liability. There is no assurance that any of the conditions for the milestone payments will be met.

The components of contingent consideration ~~liabilities~~liability are as follows:


	June 30, 2020		March 31, 2020		September 30, 2020		March 31, 2020
	(in $000's)				(in $000's)
ECP	$	9,801	$	9,000	$	10,117	$	9,000
Breethe, Inc.		13,900		—		14,300		—
	$	23,701	$	9,000	$	24,417	$	9,000

In July 2014, the Company acquired ECP and AIS GmbH Aachen Innovative Solutions (“AIS”) for $13.0 million in cash, with additional potential payouts totaling $15.0 million based on the achievement of CE Mark approval in the European Union and a revenue-based milestone related to the development of the future Impella ECP^TM expandable catheter pump technology. These potential milestone payments may be made, at the Company’s option, by a combination of cash or ABIOMED common stock.

The Company used a combination of an income approach, based on various revenue and cost assumptions and applying a probability to each outcome and a Monte-Carlo valuation model, both of which consider significant unobservable inputs. For the clinical and regulatory milestone, probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn out itself, the related projections, and the overall business. The revenue-based milestone is valued using a Monte-Carlo valuation model, which simulates estimated future revenues during the earn out-period using management’s best estimates.

Key unobservable inputs include the discount rate used to present value the projected revenues and cash flows (ranging from 2% to 16%), the probability of achieving the various technical, regulatory and commercial milestones ~~of 63%~~(estimated to be 65%) and projected revenues, which are based on the Company’s most recent internal operational budgets and long-range strategic plans.

In April 2020, the Company acquired Breethe, Inc. for $55.0 million in cash, with additional potential payouts up to a maximum of $55.0 million payable based on the achievement of certain technical, regulatory and commercial milestones.

The Company used a combination of an income approach, based on various revenue and cost assumptions and applying a probability to each outcome and a Monte-Carlo valuation model, both of which consider significant unobservable inputs. For the regulatory milestones, probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn out itself, the related projections, and the overall business. The commercial milestones are valued using a Monte-Carlo valuation model, which simulates estimated future revenues during the earn out-period using management’s best estimates.

Key unobservable inputs include the discount rates used to present value the projected revenues and cash flows (ranging from 3%2% to ~~15%~~16%), the probability of achieving the various technical, regulatory and commercial milestones ~~(ranging~~(estimated to range from 25% to ~~95%~~99%) and projected revenues, which are based on the Company’s most recent internal operational budgets and long-range strategic plans.

Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 1 primarily consists of financial instruments whose values are based on quoted market prices such as exchange-traded instruments and listed equities.

Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.

Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.

The following tables present the Company’s fair value hierarchy for its financial instruments measured at fair value as of ~~June~~September 30, 2020 and March 31, 2020:

	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
June 30, 2020	(in $000's)
September 30, 2020									(in $000's)
Assets
Money market funds	$	130,012	$	—	$	—	$	130,012	$	104,305	$	—	$	—	$	104,305
Repurchase agreements		—		20,000		—		20,000		—		20,000		—		20,000
Short-term U.S. Treasury mutual fund securities		—		42,407		—		42,407
Short-term government-backed securities		—		40,131		—		40,131		—		85,456		—		85,456
Short-term corporate debt securities		—		110,014		—		110,014		—		129,781		—		129,781
Short-term commercial paper		—		19,984		—		19,984		—		40,017		—		40,017
Short-term U.S. Treasury mutual fund securities										—		75,589		—		75,589
Long-term U.S. Treasury mutual fund securities										—		10,248		—		10,248
Long-term government-backed securities		—		75,544		—		75,544		—		141,536		—		141,536
Long-term corporate debt securities		—		94,124		—		94,124		—		50,829		—		50,829
Cross-currency swap agreement		—		1,504		—		1,504
Investment in Shockwave Medical		79,527		—		—		79,527		22,494		—		—		22,494
Liabilities
Contingent consideration		—		—		23,701		23,701		—		—		24,417		24,417

Cross-currency swap agreement										—		2,860		—		2,860

	Level 1		Level 2		Level 3		Total
March 31, 2020	(in $000's)
Assets
Money market funds	$	115,019	$	—	$	—	$	115,019
Repurchase agreements		—		20,000		—		20,000
Short-term U.S. Treasury securities		—		42,648		—		42,648
Short-term government-backed securities		—		67,995		—		67,995
Short-term corporate debt securities		—		107,301		—		107,301
Short-term commercial paper		—		32,831		—		32,831
Long-term government-backed securities		—		91,064		—		91,064
Long-term corporate debt securities		—		116,731		—		116,731
Cross currency swap agreement		—		3,786		—		3,786
Investment in Shockwave Medical		55,704		—		—		55,704
Liabilities
Contingent consideration		—		—		9,000		9,000

The Company has determined that the estimated fair value of its money market funds and its investment in Shockwave Medical, Inc. (“Shockwave Medical”) a publicly traded medical device company, are reported as Level 1 financial assets as they are valued at quoted market prices in active markets. The investment in Shockwave Medical is classified within other assets in the consolidated balance sheet.

The Company has determined that the estimated fair value of its repurchase agreements, U.S. Treasury mutual fund securities, government-backed securities, corporate debt securities and commercial paper and cross-currency swap agreement are reported as Level 2 financial assets as they are based on model-driven valuations in which all significant inputs are observable, or can be derived from or corroborated by observable market data for substantially the full term of the asset.

This contingent consideration liability is reported as Level 3 as the estimated fair value of the contingent consideration related to the acquisitions of ECP and Breethe, Inc. require significant management judgment or estimation and is calculated as described above.

The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the three and six months ended ~~June~~September 30, 2020 and 2019:

		For the Three Months Ended June 30,					For the Three Months Ended September 30,				For the Six Months Ended September 30,
			2020		2019			2020		2019		2020		2019
		(in $000's)					(in $000's)
Beginning balance	Beginning balance	$	9,000	$	9,575	Beginning balance	$	23,701	$	9,931	$	9,000	$	9,575
Additions	Additions		13,900		—	Additions		0		0		13,300		0
Payments			—		—
Change in fair value	Change in fair value		801		356	Change in fair value		716		305		2,117		661
Ending balance	Ending balance	$	23,701	$	9,931	Ending balance	$	24,417	$	10,236	$	24,417	$	10,236

The change in fair value of the contingent consideration was primarily due to the addition of contingent consideration related to the Breethe acquisition and the passage of time impact on fair value measurements.

	June 30, 2020			March 31, 2020			September 30, 2020			March 31, 2020
	(in $000's)						(in $000's)
Land	$	7,266		$	7,179		$	7,454		$	7,179
Building and building improvements		101,155			100,176			102,644			100,176
Leasehold improvements		15,010			14,546			15,183			14,546
Machinery and equipment		75,861			71,636			78,343			71,636
Furniture and fixtures		14,967			14,600			15,166			14,600
Construction in progress		20,211			15,075			26,277			15,075
Total cost		234,470			223,212			245,067			223,212
Accumulated depreciation		(64,124	)		(58,281	)		(69,485	)		(58,281	)
Property and equipment, net	$	170,346		$	164,931		$	175,582		$	164,931

The carrying amount of goodwill at ~~June~~September 30, 2020 and March 31, 2020 was ~~$76.8~~$78.1 million and $32.0 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, in May 2005, ECP in July 2014 and Breethe, Inc. in April 2020. The carrying value of goodwill and the change in the balance for the ~~three~~six months ended ~~June~~September 30, 2020 are as follows:

	(in $000's)		(in $000's)
Balance, March 31, 2020	$	31,969	$	31,969
Breethe, Inc. acquisition		44,149		44,048
Foreign currency translation impact		665		2,105
Balance, June 30, 2020	$	76,783
Balance, September 30, 2020			$	78,122

The Company evaluates goodwill at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has 0 accumulated impairment losses on goodwill.

The carrying amount of IPR&D assets at ~~June~~September 30, 2020 and March 31, 2020 was ~~$42.2~~$42.9 million and $14.9 million, respectively, and was recorded in conjunction with the Company’s acquisition of ECP and AIS, in July 2014 and Breethe, Inc, in April 2020.

	June 30, 2020		March 31, 2020		September 30, 2020		March 31, 2020
	(in $000's)				(in $000's)
ECP	$	15,223	$	14,913	$	15,895	$	14,913
Breethe, Inc.		27,000		—		27,000		—
	$	42,223	$	14,913	$	42,895	$	14,913

The estimated fair value of IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for the future Impella ECP^TM expandable catheter pump and the future Abiomed Breethe OXY-1 ~~system ECMO technology~~System were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used discount rates ranging from 15% to 21% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the ~~three~~six months ended ~~June~~September 30, 2020 are as follows:

	(in $000's)		(in $000's)
Balance, March 31, 2020	$	14,913	$	14,913
Breethe, Inc. acquisition		27,000		27,000
Foreign currency translation impact		310		982
Balance, June 30, 2020	$	42,223
Balance, September 30, 2020			$	42,895

The Company evaluates IPR&D assets at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has 0 accumulated impairment losses on IPR&D assets.

	June 30, 2020		March 31, 2020		September 30, 2020		March 31, 2020
	(in $000's)				(in $000's)
Investment in Shockwave Medical	$	79,527	$	55,704	$	22,494	$	55,704
Other investments	$	38,741	$	38,741		39,041		38,741
Operating lease right of use asset (Note 8)		11,673		11,760		11,021		11,760
Cross currency swap (Note 6)		1,504		3,786		—		3,786
Other intangible assets and other assets		8,483		7,664		10,038		7,664
Total other assets	$	139,928	$	117,655	$	82,594	$	117,655

The fair value of the Company’s investment in Shockwave Medical, a publicly-traded medical device company, was ~~$79.5~~$22.5 million and $55.7 million as of ~~June~~September 30, 2020 and March 31, 2020, respectively. ~~Amounts~~During the three and six months ended September 30, 2020, amounts recorded in other income (expense), net of tax, were ~~$23.8~~gains of $8.2 million and ~~$39.7~~$26.2 million, ~~for~~respectively. During the three and six months ended ~~June~~September 30, 2019, amounts recorded in other income (expense), net of tax, were losses of $34.5 million and $4.5 million, respectively. During the quarter ended September 30, 2020, the Company sold approximately 1.4 million of its shares for cash proceeds of $67.9 million and ~~2019, respectively.~~total realized gain of $47.3 million. The Company held 0.3 million shares of Shockwave Medical at September 30, 2020.

The carrying value of the Company’s portfolio of other investments and the change in the balance for the three and six months ended ~~June~~September 30, 2020 and 2019 are as follows:

	For the Three Months Ended June 30,					For the Three Months Ended September 30,					For the Six Months Ended September 30,
		2020			2019		2020			2019		2020			2019
	(in $000's)					(in $000's)
Beginning balance	$	38,741		$	24,584	$	38,741		$	26,584		38,741			24,584
Additions		2,000			2,000		1,100			5,000		3,100			7,000
Reclassification		(2,000	)		—		—			—		(2,000	)		—
Change in fair value, net		—			—
Impairment							(800	)		—		(800	)		—
Ending balance	$	38,741		$	26,584	$	39,041		$	31,584	$	39,041		$	31,584

During the three and six months ended September 30, 2020, the Company recorded an impairment loss of $0.8 million in other (expense) income relating to certain of the Company’s investment in other private medical device companies.

Included within other intangible assets and other is $4.1 million related to license manufacturing rights to certain technology from third parties. These intangible assets are classified with other assets in the Company’s consolidated balance sheet and are amortized over their useful life of 15 years.

The following table presents supplemental balance sheet information related to our operating leases:

	June 30, 2020		March 31, 2020		September 30, 2020		March 31, 2020
	(in $000's)				(in $000's)
Assets
Operating lease right-of-use assets in other assets	$	11,673	$	11,760	$	11,021	$	11,760
Liabilities
Operating lease liabilities in other current liabilities		3,751		3,671		3,683		3,671
Operating lease liabilities in other long-term liabilities		8,366		8,549		7,807		8,549
Total operating lease liabilities	$	12,117	$	12,220	$	11,490	$	12,220

Expense charged to operations under operating leases ~~was $1.7~~were $1.1 million and ~~$1.1~~$2.2 million during each of the three and six months ended ~~June~~September 30, 2020 and 2019, respectively. ~~Short-term lease expenses were not material.~~

Maturities of lease liabilities as of ~~June~~September 30, 2020 are as follows:

(in thousands, except lease term and discount rate)	(in thousands, except lease term and discount rate)				(in thousands, except lease term and discount rate)

Fiscal Years Ended March 31,
2021		$	3,133			$	2,153
2022			2,956				3,088
2023			1,844				1,925
2024			1,734				1,782
2025			1,547				1,578
Thereafter			2,002				2,033
Total minimum lease payments			13,216				12,559
Less: imputed interest			(1,099	)			(1,069	)
Present value of operating lease liabilities		$	12,117			$	11,490

Weighted average remaining lease term		5.05				4.99

Weighted average discount rate			3.15	%			3.14	%

	June 30, 2020		March 31, 2020		September 30, 2020		March 31, 2020
	(in $000's)				(in $000's)
Employee compensation	$	22,544	$	32,273	$	29,081	$	32,273
Sales and income taxes		22,329		21,641		11,239		21,641
Research and development		4,225		5,749		5,481		5,749
Professional, legal, and accounting fees		1,964		6,880		3,320		6,880
Warranty		1,626		1,818		1,739		1,818
Marketing		1,102		1,705		1,092		1,705
Other		4,641		5,041		5,275		5,041
	$	58,431	$	75,107	$	57,227	$	75,107

The accrual for employee compensation consists primarily of accrued bonuses, commissions, employee benefits and payroll taxes ~~(on equity awards)~~ at ~~June~~September 30, 2020 and March 31, 2020.

The Company has authorized 1,000,000 shares of Class B Preferred Stock, $.01 par value, of which the board of directors can set the designation, rights and privileges. NaN shares of Class B Preferred Stock have been issued or are outstanding.

In August 2019, the Company’s Board of Directors authorized a stock repurchase program for up to $200.0 million of shares of its common stock. Under this stock repurchase program, the Company is authorized to repurchase shares through open market purchases, privately negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The stock repurchase program has no time limit and may be suspended for periods or discontinued at any time. The Company is funding the stock repurchase program with its available cash and marketable securities. ~~During~~The Company did not make any repurchases during the three months ended ~~June~~September 30, ~~2020, the Company has repurchased a total of 67,649 shares for $11.3 million under the stock repurchase program.~~2020. The remaining authorization under the stock repurchase program was $103.8 million as ~~June~~September 30, 2020.

The following table provides shares bought through stock repurchase ~~activities~~program during the ~~quarter:~~three and six months ended September 30, 2020 and 2019:

	For the Three Months Ended June 30,				For the Three Months Ended September 30,				For the Six Months Ended September 30,
	2020		2019		2020		2019		2020		2019
Shares repurchased		67,649		—		—		180,929		67,649		180,929
Average price per share	$	167.19		—		—	$	192.75	$	167.19	$	192.75
Value of shares repurchased (in millions)	$	11.3		—		—	$	34.9	$	11.3	$	34.9

The components of accumulated other comprehensive income (loss), are as follows (in thousands):

	Three Months Ended June 30, 2020											Six Months Ended September 30, 2020
	Foreign Currency Translation Gains (Losses)			Unrealized Gains on Investments		Gains (Losses) on Derivative Instruments			Total			Foreign Currency Translation Gains (Losses)			Unrealized Gains on Investments			Gains (Losses) on Derivative Instruments			Total
Balance, April 1, 2020		(16,860	)		1,672		3,999			(11,189	)		(16,860	)		1,672			3,999			(11,189	)
Other comprehensive income (loss)		1,360			1,755		(461	)		2,654			1,360			1,755			(461	)		2,654
Balance, June 30, 2020		(15,500	)		3,427		3,538			(8,535	)		(15,500	)		3,427			3,538			(8,535	)
Other comprehensive income (loss)													2,416			(814	)		(266	)		1,336
Balance, September 30, 2020													(13,084	)		2,613			3,272			(7,199	)

Three Months Ended June 30, 2019

Foreign Currency Translation Gains (Losses)

Unrealized Gains on Investments

Gains (Losses) on Derivative Instruments

Total

Balance, April 1, 2019

(15,028
)

339

—

(14,689
)
Other comprehensive income (loss)

2,334

600

—

2,934

Balance, June 30, 2020

(12,694
)

939

—

(11,755
)

	Six Months Ended September 30, 2019
	Foreign Currency Translation Gains (Losses)			Unrealized Gains on Investments			Gains (Losses) on Derivative Instruments		Total
Balance, April 1, 2019		(15,028	)		339			—		(14,689	)
Other comprehensive income		2,334			600			—		2,934
Balance, June 30, 2019		(12,694	)		939			—		(11,755	)
Other comprehensive income		(5,716	)		(85	)		—		(5,801	)
Balance, September 30, 2019		(18,410	)		854			—		(17,556	)

The following table summarizes stock-based compensation expense by financial statement line item in the Company’s condensed consolidated statements of operations for the three and six months ended ~~June~~September 30, 2020 and 2019:

	For the Three Months Ended June 30,				For the Three Months Ended September 30,				For the Six Months Ended September 30,
��						2020		2019		2020		2019
		2020		2019	(in $000's)
	(in $000's)
Cost of product revenue	$	705	$	841
Cost of revenue					$	923	$	881	$	1,627	$	1,722
Research and development		1,442		1,883		1,705		1,823		3,147		3,706
Selling, general and administrative		7,151		10,397		8,937		10,619		16,089		21,017
	$	9,298	$	13,121	$	11,565	$	13,323	$	20,863	$	26,445

The following table summarizes the stock option activity for the ~~three~~six months ended ~~June~~September 30, 2020:

						Weighted									Weighted
				Weighted		Average		Aggregate					Weighted		Average		Aggregate
				Average		Remaining		Intrinsic					Average		Remaining		Intrinsic
	Options			Exercise		Contractual		Value		Options			Exercise		Contractual		Value
	(in thousands)			Price		Term (years)		(in thousands)		(in thousands)			Price		Term (years)		(in thousands)
Outstanding at beginning of period		869		$	112.03		5.30				869		$	112.03		5.30
Granted		64			220.13						65			221.12
Exercised		(31	)		32.12						(153	)		36.41
Cancelled and expired		(4	)		238.28						(8	)		227.25
Outstanding at end of period		898		$	121.95		5.53	$	119,849		774		$	134.90		5.77	$	117,144
Exercisable at end of period		707		$	87.62		4.60	$	116,169		592		$	98.68		4.84	$	110,352
Options vested and expected to vest at end of period		896		$	121.96		5.53	$	119,698		773		$	134.92		5.77	$	117,040

Stock options generally vest and become exercisable annually over three years. The remaining unrecognized stock-based compensation expense for unvested stock option awards at ~~June~~September 30, 2020, was approximately ~~$15.3~~$13.0 million and the estimated weighted-average period over which this cost will be recognized is ~~2.0~~1.9 years.

The aggregate intrinsic value of stock options exercised was ~~$5.0~~$37.8 million for the ~~three~~six months ended ~~June~~September 30, 2020. The total cash received as a result of employee stock option exercises for the ~~three~~six months ended ~~June~~September 30, 2020, was approximately ~~$1.0~~$5.6 million.

The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The weighted average grant-date fair values and weighted average assumptions used in the calculation of fair value of options granted during the three and six months ended ~~June~~September 30, 2020 and 2019 was as follows:

	For the Three Months Ended June 30,						For the Three Months Ended September 30,						For the Six Months Ended September 30,
		2020			2019			2020			2019			2020			2019
Weighted average grant-date fair value	$	75.75		$	96.30		$	100.51		$	70.40		$	76.10		$	95.62

Valuation assumptions:
Risk-free interest rate		0.31	%		2.03	%		0.30	%		1.54	%		0.31	%		2.02	%
Expected option life (years)		4.22			4.14			4.17			4.13			4.22			4.14
Expected volatility		42.8	%		42.3	%		43.5	%		44.2	%		42.82	%		42.3	%

The following table summarizes activity of restricted stock units for the ~~three~~six months ended ~~June~~September 30, 2020:

	Number of Shares			Weighted Average Grant Date Fair Value		Number of Shares			Weighted Average Grant Date Fair Value
	(in thousands)			(per share)		(in thousands)			(per share)
Restricted stock units at beginning of period		320		$	263.92		320		$	263.92
Granted		164			247.01		194			254.55
Vested		(124	)		229.22		(136	)		226.71
Forfeited		(100	)		267.72		(101	)		267.28
Restricted stock units at end of period		260		$	268.13		277		$	274.31

Restricted stock units generally vest annually over three years. The remaining unrecognized compensation expense for outstanding restricted stock units, including performance and market-based awards, as of ~~June~~September 30, 2020 was ~~$59.0~~$59.3 million and the estimated weighted-average period over which this cost will be recognized is ~~2.4~~2.1 years.

The weighted average grant-date fair value for restricted stock units granted during the ~~three~~six months ended ~~June~~September 30, 2020 was ~~$247.01.~~$254.55. The total fair value of restricted stock units vested during the ~~three~~six months ended ~~June~~September 30, 2020 was ~~$23.3~~$26.8 million.

In May 2020, performance-based awards of restricted stock units for the potential issuance of up to 61,674 shares of common stock were issued to certain executive officers and employees, which vest upon achievement of prescribed service milestones by the award recipients and the achievement of prescribed performance milestones by the Company. As of ~~June~~September 30, 2020, the Company is recognizing compensation expense based on the probable outcomes related to the prescribed performance targets on the outstanding awards.

In ~~June~~May 2020, the Company awarded certain executive officers and employees a total of up to 61,562 market-based restricted stock units. These restricted stock units will vest and result in the issuance of shares of common stock based on continuing employment and the relative ranking of the total shareholder return (“TSR”) of the Company’s common stock in relation to the TSR of twenty peer companies over a two-year and three-year performance period based on a comparison of average closing stock prices during the 20 trading days prior to the first day of the performance period, reinstated dividends during each performance period and the average closing stock prices during the final 20 trading days of each performance period. The actual number of market-based restricted stock units that may be earned can range from 0% to 200% of the target number of shares. Additionally, the payout percentage is further adjusted based on the Company’s performance relative to the constituents of the S&P 500 Index on the first day of the performance period that are still actively trading on the last day of each performance period. The restricted stock units will vest following the end of the two-year and three-year performance period, respectively.

The Company used a Monte-Carlo simulation model to estimate the grant-date fair value of the TSR restricted stock units. The fair value related to these awards are recorded as compensation expense over the period from date of grant to May 2022 and May 2023, respectively, regardless of the actual TSR outcome reached.

The table below sets forth the assumptions used to value the awards and the estimated grant-date fair value:

The Company’s income tax provision was ~~$16.5~~$10.7 million and $4.3 million for the three months ended ~~June~~September 30, 2020 and ~~the~~2019, respectively. The Company’s income tax provision was ~~$14.2~~$27.2 million and $18.5 million for the ~~three~~six months ended ~~June~~September 30, ~~2019.~~2020 and 2019, respectively. The Company’s effective tax rate was ~~27.0%~~14.7% and ~~13.8%~~24.7% for the three

months ended ~~June~~September 30, 2020 and 2019, respectively.The Company’s effective tax rate was 20.3% and 15.4% for the six months ended September 30, 2020 and 2019, respectively. The Company’s U.S. federal statutory corporate income tax rate of 21% was applied in the computation of the income tax provision for the three and six months ended ~~June~~September 30, 2020 and 2019.

The significant differences between the statutory income tax rate and effective income tax rate for the three and six months ended ~~June~~September 30, 2020 and 2019 were as follows:

	For the Three Months Ended June 30,							For the Three Months Ended September 30,							For the Six Months Ended September 30,
		2020			2019				2020			2019				2020			2019
Statutory income tax rate		21.0		%	21.0		%		21.0		%	21.0		%		21.0		%	21.0		%
Increase (decrease) resulting from:																			—
Excess tax benefits from stock-based awards		(0.9	)		(12.4	)			(10.9	)		(2.7	)			(6.3	)		(11.0	)
Credits		(1.9	)		(1.6	)			(1.7	)		(2.1	)			(1.7	)		(1.7	)
State taxes, net		3.9			3.4				4.1			3.3				4.1			3.4
Permanent differences		5.0			1.9				2.6			1.7				3.4			1.9
Excess foreign tax credit									0.4			—				0.4			—
Other		(0.1	)		1.4				(0.8	)		3.5				(0.6	)		1.7
Effective tax rate		27.0		%	13.8		%		14.7		%	24.7		%		20.3		%	15.4		%

The Company recognizes excess tax benefits and shortfalls in the income tax provision as discrete items in the period in which restricted stock units vest or stock option exercises occur. The Company recognized excess tax benefits associated with stock-based awards of ~~$0.5~~$7.9 million and ~~$12.8~~$0.5 million as an income tax benefit for the three months ended ~~June~~September 30, 2020 and 2019, respectively. The Company recognized excess tax benefits associated with stock-based awards of $8.5 million and $13.3 million for the six months ended September 30, 2020 and 2019. These recognized excess tax benefits resulted from restricted stock units that vested or stock options that were exercised during each period. The amount of future excess tax benefits or shortfalls will likely fluctuate from period to period based on the price of the Company’s stock, the number of restricted stock units that vest or stock options that are exercised, and the fair value assigned to such stock-based awards under U.S. GAAP.

The Company is subject to the examination of its income tax returns by the Internal Revenue Service (“IRS”) and other tax authorities. The outcome of these audits cannot be predicted with certainty. The Company’s management regularly assesses the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of the Company’s provision for income taxes. If any issues addressed in the Company’s tax audits are resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs. The Company’s most recent completed income tax audits were in the U.S. relating to fiscal year 2016 and in Germany, which covered fiscal years 2012 through 2015. These tax audits did not materially impact our financial statements. On October 29, 2020, the Company was notified by the German tax authorities that they will be conducting an income tax audit on Abiomed Europe GMBH and ECP for fiscal years 2016 through 2019 beginning in January 2021. All other tax years remain subject to examination by the federal, state and foreign tax authorities.

On March 27, 2020 the House passed the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), and the President of the United States signed the legislation into law. The Company does not expect the provisions of the legislation to have a significant impact on the effective tax rate or the income tax payable and deferred income tax positions of the Company.

From time to time, the Company is involved in legal and administrative proceedings and claims of various types. In some actions, the claimants seek damages, as well as other relief, which, if granted, would require significant expenditures. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.

Thoratec Corporation (“Thoratec”), a subsidiary of Abbott Laboratories (“Abbott”), has challenged a number of Company-owned patents in Europe in connection with the launch of Thoratec’s HeartMate PHP™ medical device (“PHP”) in Europe and the Company has counterclaimed for infringement in the District Court in Düsseldorf. The litigation was stayed pending the highest Court’s ruling on the validity and scope of the litigated patents. In September 2019, the Federal Court of Justice in Germany upheld the Company’s patents that are the subject of the patent infringement action for the sales and marketing of Thoratec’s PHP pump in Germany. Subsequently, the District Court in Düsseldorf lifted the stay, ~~and~~ re-opened the litigation ~~proceedings.~~proceedings, and ruled in favor of Abiomed. The Court acknowledged that Thoratec’s PHP product infringes two of Abiomed patents related to the key features of Impella® intravascular pump and future expandable heart pump, known as Impella ECP®. Abbott appealed and the oral hearing is set for August 21, 2021. If upheld, the verdict is provisionally enforceable, which means that Abiomed will be able to seek a court ordered injunction preventing the sale and marketing of PHP, should Thoratec attempt to launch HeartMate PHP in Germany.

These actions relate solely to Thoratec’s ability to manufacture and sell its PHP product in Europe and have no impact on the Company's ability to manufacture or sell its Impella® line of medical devices. The actions do not expose the Company to liability risk, except under local German law that requires a losing party in a proceeding to pay a portion of the other party’s legal fees.

In December 2015, the Company received a letter from Maquet Cardiovascular LLC (“Maquet”), a subsidiary of Getinge AB, asserting that the Company’s Impella^® devices infringe certain claims with guidewire, lumen, rotor, purge and sensor features, which were in two Maquet patents and one pending patent application (which has since issued as a third patent) in the U.S. and elsewhere, and attaching a draft litigation complaint. The letter encouraged the Company to take a license from Maquet. In May 2016, the Company filed suit in U.S. District Court for the District of Massachusetts (“D. Mass.” or “the Court”) against Maquet, seeking a declaratory judgment that the Company’s Impella devices do not infringe Maquet’s cited patent rights. ~~The three Maquet patents will expire in September 2020, December 2020 and October 2021.~~

In August 2016, Maquet sent a letter to the Company identifying four new Maquet U.S. continuation patent filings with claims that Maquet alleges are infringed by the Company’s Impella devices. The four U.S. continuation applications have been issued as patents of Maquet ~~and will expire in~~but expired on September 1, 2020.

In September 2016, Maquet filed a response to the Company’s suit in D. Mass., including various counterclaims alleging that the Company’s Impella 2.5®, Impella CP®, Impella 5.0®, and Impella RP® heart pumps infringe certain claims of the three original issued U.S. patents (“2016 Action”). In July 2017, the Court granted a motion to add three of the four additional continuation patents to the 2016 Action. In April 2018, the Court conducted a Markman hearing on claim interpretation. On September 7, 2018, the judge issued a Memorandum and Order on Claim Construction, where he interpreted the disputed claim terms in the case. Maquet then filed a motion for reconsideration of the Court’s construction of one of the disputed claim terms. The motion was denied on May 22, 2019. As a result of the Court’s denial, only one of the six originally asserted patents is in dispute. The Company filed a motion for summary judgement (MSJ) for the remaining patent on September 18, 2019 (non-infringement) and April 13, 2020 (invalidity). The parties ~~briefed~~argued the MSJ for non-infringement on November 19, 2019, the MSJ for invalidity on August 20, 2020 and are waiting for Court’s resolution. The Court has not set a date for trial. The only remaining patent asserted in this case expired on September 1, 2020.

In November 2017, Maquet filed a second action in D. Mass (“2017 Action”) alleging that the Company’s Impella 2.5®, Impella CP®, and Impella 5.0® heart pumps infringe certain claims of the fourth additional U.S. continuation patent mentioned above (the seventh patent overall). Discovery in the 2017 Action is ongoing.

In a series of letters during January and February 2019, Maquet informed the Company of seven new patent applications filed from the patents in the 2016 Action and 2017 Action with claims Maquet alleges would be infringed by the Impella® products if the new applications were to issue as patents. ~~All seven applications issued as patents between February 2019 and July 2019 and will expire in September 2020.~~ One of the newly issued patents has been added to the 2017 Action. A Markman hearing for the newly-added patent was held on November 18, 2019. A Markman order has not been issued yet. The asserted patent in this case expired on September 1, 2020. Discovery remains ongoing.

In the 2016 Action and 2017 Action, Maquet seeks injunctive relief and monetary damages in the form of a reasonable royalty, with three times the amount for alleged willful infringement. In its responses to the Company’s counterclaims, Maquet admits that its current commercially available products do not embody the claims of the asserted patents.

The Company is unable to estimate the potential liability with respect to the legal matters noted above. There are numerous factors that make it difficult to meaningfully estimate possible loss or range of loss at this stage of the legal proceedings, including the significant number of legal and factual issues still to be resolved in the Maquet and Thoratec patent disputes.

On or about August 6, 2019, the Company received a securities class action complaint filed on behalf of a single shareholder in the U.S. District Court for the Southern District of New York (“SDNY”), on behalf of himself and persons or entities that purchased or acquired the Company’s securities between January 31, 2019 through July 31, 2019. On October 7, 2019, a similar purported class action complaint was filed by a different shareholder on behalf of himself and persons or entities that purchased or acquired the Company’s securities between November 1, 2018 and July 31, 2019. Also, on October 7, 2019, four shareholders filed applications to be appointed lead plaintiff and for their counsel to be appointed lead counsel for the class. Two of those shareholders also filed motions to consolidate the two cases and two of the shareholders have withdrawn their applications to be lead plaintiff.

The complaints allege that the Company violated Sections 10(b) and 20(a) of and Rule 10b-5 under the Exchange Act, in connection with allegedly misleading disclosures made by the Company regarding its financial condition and results of operations. The Company has reviewed and not yet responded to the complaints. The Company believes that the allegations are without merit and plans to defend itself vigorously.

On June 28, 2020, the Court issued an order consolidating the two cases and appointed Local 705 International Brotherhood of Teamsters Pension Fund as the lead plaintiff and the Labaton Sucharow firm as lead counsel. ~~The Company and~~On September 17, 2020, the lead plaintiff ~~have stipulated that~~filed an amended ~~consolidated~~ complaint ~~will be filed~~in which they proposed a new class period of May 3, 2018 to July 31, 2019. As prescribed by a scheduling order, the ~~lead plaintiff by September 17,~~Company may file a motion to dismiss on or before November 16, 2020. The Company ~~then~~ intends to ~~respond to~~do so but does not expect a decision on that ~~complaint.~~ motion until at least the second quarter of calendar year 2021.

On November 6 and 7, 2019, two shareholders filed derivative actions in SDNY that were subsequently consolidated. On November 8, 2019, another shareholder filed a derivative action in Massachusetts Suffolk County Superior Court. On January 7, 2020, another shareholder derivative action was filed in the U.S. District Court for the District of Delaware. The complaints in these actions rely on many of the same allegations as in the securities class actions, and assert that, between November 1, 2018 and July 31, 2019, the directors of the Company made or allowed to be made misleading public statements regarding the Company’s growth, ultimately harming the Company.

The Company has agreed with the plaintiffs in all three actions to stay the cases pending resolution of a motion to dismiss in the securities class actions. As a result of the stay, the Delaware action has been administratively closed.

On March 3, 2020, a shareholder sent a letter to the Board of Directors asserting that the directors of the Company made or allowed to be made misleading public statements regarding the Company’s growth. The letter relies on many of the same allegations as the securities class actions and derivative actions, and demands that the Board (i) undertake an independent investigation of the directors, (ii) bring suit against the directors on behalf of the Company, and (iii) take a number of additional affirmative actions to redress the purported wrongs. On March 30, 2020, the Company, after discussions with the Board of Directors, sent a written response to the shareholder’s counsel which they responded to on June 1, 2020. The Company then sent a further response to the shareholder’s counsel on June 15, 2020, affirming the decision to defer consideration of the litigation demand pending further developments in the securities class action suit. Following the filing of the amended complaint in the securities class action, described above, the same shareholder renewed their demand on September 29, 2020. The Company responded on October 9, 2020 and once again affirmed that it will defer consideration of the demand pending further substantive developments in the securities class action suit.

The Company is unable to estimate the potential liability with respect to the various legal matters noted above. There are numerous factors that make it difficult to estimate reasonably possible loss or range of loss at this stage of the legal proceedings, including the significant number of legal and factual issues still to be resolved in the securities class action litigation, as well as in the shareholder derivative litigations.

The Company operates in 1 business segment: the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. International sales (meaning sales outside the U.S., primarily in ~~Europe)~~Europe and Japan) accounted for 18% and ~~15%~~16% of total revenue for each of the three and six months ended ~~June~~September 30, 2020 and 2019, respectively. The Company’s long-lived assets are located in the U.S., except for ~~$48.9~~$52.9 million and $46.7 million at ~~June~~September 30, 2020 and March 31, 2020, respectively, which are located primarily in Germany.

This Report, including the documents incorporated by reference in this Report, includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Each forward-looking statement in this Report is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Factors that could cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include: the impact of the COVID-19 pandemic, efforts to contain the pandemic and resulting economic downturn on our operations and financial condition; our dependence on Impella® products for all of our revenues; our ability to successfully compete against our existing or potential competitors; the acceptance of our products by cardiac surgeons and interventional cardiologists, especially those with significant influence over medical device selection and purchasing decisions; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of our products due to lengthy clinician training process; our ability to effectively manage our growth; our ability to successfully commercialize our products; our ability to obtain regulatory approvals and market and sell our products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of our products; unsuccessful clinical trials or procedures relating to products under development; our ability to maintain compliance with regulatory requirements; mandatory or voluntary product recalls; shutdowns of the U.S. federal government; third-party payers’ failure to provide reimbursement of our products; changes in healthcare reimbursement systems in the U.S. and other foreign jurisdictions; our failure to comply with healthcare “fraud and abuse” laws; our failure to comply with the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations; uncertainties associated with our product development efforts; our ability to increase manufacturing capacity to support continued demand for our products; our or our vendors’ failure to achieve and maintain high manufacturing standards; our ability to attract and retain key personnel; our suppliers’ failure to provide the components we require; our ability to expand our direct sales activities into international markets; the economic effects of “Brexit”; poor performance of our distributors in the international markets; our ability to sustain profitability; our potential “ownership change” for U.S. federal income tax purposes and our limited utilization of net operating losses from prior tax years; impact of changes in tax laws, including recently enacted U.S. Tax Reform; our ability to develop and commercialize new products or acquire desirable companies, products or technologies; our failure to protect our intellectual property or develop or acquire additional intellectual property; increased risk of material product liability claims; inventory write-downs and other costs due to product quality problems; liabilities due to failure to protect the confidentiality of patient health information; disruptions of critical information systems or material breaches in the security of our systems; risks and liabilities associated with acquisitions of other companies or businesses; changes in accounting standards, tax laws and financial reporting requirements; liabilities, expenses and restrictions associated with environmental and health safety laws; changes in methods, estimates and judgments we use in applying our accounting policies; fluctuations in foreign currency exchange rates; the outcome of ongoing securities class action litigation relating to our public disclosures; and other factors discussed in Part I, Item 1A. Risk Factors of our Form 10-K for the year ended March 31, 2020 and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Report. Unless otherwise required by law, we undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Report or to reflect the occurrence of unanticipated events.

We are a leading provider of temporary mechanical circulatory support devices, and we offer a continuum of care to heart failure patients. We develop, manufacture and market proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily assisting the pumping function of the heart. Our products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by cardiac surgeons. A physician may use our devices for patients who are in need of hemodynamic support prophylactically, urgently or emergently before, during or after angioplasty or heart surgery procedures. We believe that heart recovery is the optimal clinical outcome for a patient experiencing heart failure because it enhances the potential for the patient to go home with their own heart, facilitating the restoration of quality of life. In addition, we believe that, for the care of such patients, heart recovery is often the most cost-effective solution for the healthcare system.

Our strategic focus and the driver of our revenue growth is the market penetration of our family of Impella® heart pumps. The Impella device portfolio, which includes the Impella 2.5®, Impella CP®, Impella 5.0®, Impella LD®, Impella 5.5® and Impella RP® devices, has supported thousands of patients worldwide. We expect that most of our product and service revenue in the near future will be from our Impella devices. Our Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP devices have U.S Food and Drug Administration or FDA and CE Mark approval which allows us to market these devices in the U.S. and European Union. We expect to continue to make additional pre-market approval, or PMA supplement submissions for our Impella portfolio of devices for additional indications. Our Impella 2.5, Impella CP and Impella 5.0 devices have regulatory approval from the Ministry of Health, Labor and Welfare, or MHLW, in Japan.

In March 2020, the World Health Organization categorized the novel Coronavirus disease 2019, or (COVID-19) as a pandemic. COVID-19 continues to spread throughout the United States and other countries across the world, and the duration and severity of its effects are currently unknown. The global pandemic has adversely impacted and is likely to further adversely impact our business and markets, including our workforce and operations and the operations of our customers, suppliers, and business partners. Considerable uncertainty still surrounds the COVID-19 virus and its potential effects, and the extent of and effectiveness of responses taken on international, national and local levels. Measures taken to limit the impact of COVID-19, including shelter-in-place orders, social distancing measures, travel bans and restrictions, and business and government shutdowns, have already created significant negative economic impacts on a global basis.

Due to these impacts and measures, we have experienced, and may continue to experience, significant and unpredictable reductions in the demand for our products as healthcare customers divert medical resources and priorities towards the treatment of COVID-19. In addition, our customers may delay, cancel, or redirect planned purchases in order to focus resources on COVID-19 or in response to economic disruption related to COVID-19. Beginning in mid-March 2020 and continuing into the first quarter of fiscal 2021, wethe Company experienced a significant decline in patient utilization in the U.S., Europe and Japan as healthcare systems diverted resources to meet the increasing demands of managing COVID-19. We also experienced temporary delays in clinical trial enrollment or encountered interruption or delays in the operations of FDA or other regulatory authorities due to the COVID-19 pandemic, which may impact review and approval timelines. The severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers, all of which are uncertain and cannot be predicted.

Impella procedure volumes have varied greatly since the end of March 2020 by geography, and even by hospital, as patients and their physicians managed through the COVID-19 pandemic. In the last few weeks of the fourth quarter of fiscal 2020, procedure volumes related to our Impella products dropped significantly. Worldwide Impella heart pump revenue was impacted by lower patient utilization in the first quarter of fiscal 2021 due to the impact of the COVID-19 pandemic on elective medical procedures, surgeries and fewer patients seeking treatment at hospitals. Total revenue for the three months ended June 30, 2020 decreased by $42.8 million, or 21%, to $164.9 million from $207.7 million for the three months ended June 30, 2019. The decrease in total revenue was due to lower utilization caused by the impact of COVID-19 on hospitals in the first quarter of fiscal 2021.

During the first quarter of fiscal 2021, patient procedure volume trends began to improve gradually over the course of the quarter as both demand for procedures and availability of healthcare resources began to return to more normalized, pre-COVID-19 levels. OurCompany’s business was most impacted in April 2020, in terms of the decline in patients and revenue from the shelter-in-place restrictions in a majority of countries and limitations on procedures in hospitals. WeThe Company experienced sequential quarterly improvement globally ~~in May and June~~through the second quarter of fiscal 2021 as restrictions were lifted and limitations eased. In the ~~month~~second quarter of ~~June specifically, we experienced year over year growth in~~fiscal 2021, patient procedure volume trends have improved gradually as both ~~patients~~demand for procedures and ~~revenue in U.S., Germany, and Japan.~~availability of healthcare resources improved during the summer months.

During these challenging times, our priorities have been to support our clinician partners, protect the well-being of our employees, and maintain continuous access to our life-saving technologies while offering front-line in-hospital support. We have also taken proactive actions to mitigate the business impact of COVID-19 on our financial operations. These actions taken to date include temporary salary reductions and furloughs for certain employees, a hold on most hiring, eliminating non-critical consultants, contractors, and temporary workers, reducing discretionary spending, travel restrictions and implementing alternate work schedules for the Aachen and Danvers production teams. These actions are designed to preserve full-time jobs, preserve cash and retain the ability to ramp up quickly when demand returns, while at the same time continuing to invest in innovation.

We are closely monitoring the impact of COVID-19 on all aspects of our business and geographies, including its impact on our customers, employees, suppliers, vendors, business partners and distribution channels. The extent to which the COVID-19 global pandemic impacts our business, results of operations, and financial condition will depend on future developments, which are highly uncertain and are difficult to ~~predict;~~predict these developments include, but are not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or address its impact, U.S. and foreign government actions to respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, we may continue to experience materially adverse impacts on our financial condition and results of operations.

We acquired Breethe, Inc. (“Breethe”), a Maryland corporation, on April 24, 2020. Breethe is engaged in research and development of a novel extracorporeal membrane oxygenation (“ECMO”) system that ~~we expect~~ will complement and expand our product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including some patients suffering from cardiogenic shock or respiratory failure, such as ARDS, H1N1, SARS, or COVID-19. We acquired Breethe for $55.0 million in cash, with additional potential payouts up to a maximum of $55.0 million payable based on the achievement of certain technical, regulatory and commercial milestones. ~~An application for~~In October 2020, the Abiomed Breethe OXY-1 System received a 510(k) clearance ~~was submitted to~~from the FDA for an all-in-one, compact cardiopulmonary bypass system. Abiomed plans to have a controlled launch of the Breethe system at a limited number hospitals in ~~January 2020 and we anticipate receiving approval of this submission~~the U.S, with full U.S. commercial availability expected in fiscal ~~2021.~~year 2022.

The Impella 2.5 device is a percutaneous micro heart pump with an integrated motor and sensors. The device is designed primarily for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain circulation. The Impella 2.5 heart pump can be quickly inserted via the femoral artery to reach the left ventricle of the heart, where it is directly deployed to draw blood out of the ventricle and deliver it to the circulatory system. This function is intended to reduce ventricular work and provide blood flow to vital organs. The Impella 2.5 heart pump is introduced with normal interventional cardiology procedures and can pump up to 2.5 liters of blood per minute.

Our Impella 2.5 device has FDA and CE Mark approval which allows us to market these devices in the U.S. and European Union. We expect to continue to make additional pre-market approval, or PMA supplement submissions for our Impella portfolio of devices for additional indications. Our Impella 2.5, Impella CP and Impella 5.0 devices have regulatory approval from the Ministry of Health, Labor and Welfare, or MHLW, in Japan. The Impella 2.5 device also has Health Canada approval which allows us to market the device in Canada.

The Impella CP device provides blood flow of approximately one liter more per minute than the Impella 2.5 device and is primarily used by either interventional cardiologists to support patients in the cath lab or by cardiac surgeons in the heart surgery suite.

Our Impella CP devices has FDA and CE Mark approval which allows us to market this device in the U.S. and European Union. We expect to continue to make additional pre-market approval, or PMA supplement submissions for our Impella portfolio of devices for additional indications. In March 2019, we received PMDA approval from MHLW for our Impella CP heart pump in Japan. We began selling the Impella CP heart pump in Japan in fiscal 2020.

In April 2019, the FDA approved the initiation of the STEMI DTU ~~pivotal randomized controlled trial.~~Pivotal Randomized Controlled Trial. The prospective, multi-center, two-arm trial plans to enroll 668 patients undergoing treatment for a STEMI heart attack at up to 60 sites. Half the patients will be randomized to receive delayed reperfusion after 30 minutes of left ventricular unloading with the Impella CP. The other half will receive immediate reperfusion, the current standard of care. The trial will test the hypothesis that unloading the left ventricle for 30 minutes prior to reperfusion will reduce myocardial damage from a heart attack and lead to a reduction in future heart failure related events. The trial allows for an adaptive design, which permits adjustments to the study sample size after an interim analysis. We began the trial in ~~the third quarter of~~ fiscal 2020. In light of the ongoing COVID-19 pandemic and the related challenges presented to medical providers, we temporarily paused the trial in March 2020. We resumed the trial in the first quarter of fiscal 20212020 and we estimate that it will take three to four years to complete enrollment.

The Impella 5.0 and Impella LD devices are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5.

Our Impella 5.0 and Impella LD devices have FDA and CE Mark approval which allows us to market these devices in the U.S. and European Union. We expect to continue to make additional pre-market ~~approval,~~approvals, or PMA supplement submissions for our Impella portfolio of devices for additional indications. Our Impella 5.0 devices have regulatory approval from the Ministry of Health, Labor and Welfare, or MHLW, in Japan.

The Impella 5.5 device is designed to be a percutaneous micro heart pump with integrated motors and sensors. Impella 5.5 delivers peak flows of greater than six liters per minute. The Impella 5.5 has a motor housing that is thinner and 45% shorter than the Impella 5.0 and it improves ease of pump insertion through the vasculature.

In September 2019, the Impella 5.5 device received a PMA from the FDA for safety and efficacy in the therapy of cardiogenic shock for up to 14 days in the U.S. The Impella 5.5 pump was introduced in the U.S. through a controlled rollout at hospitals with established heart recovery protocols beginning in fiscal 2020. Impella 5.5 received CE marking approval in Europe in April 2018 and was introduced in Europe through a similar controlled rollout. We are also targeting a submission to the PMDA in Japan in fiscal 2021. The adoption of the Impella 5.5 device may lessen the utilization of Impella 5.0 and Impella LD at certain sites.

The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of blood flow per minute and is intended to provide the flow and pressure needed to compensate for right side heart failure. Our Impella RP device has FDA and CE Mark approval which allows us to market these devices in the U.S. and European Union. The Impella RP is the first

percutaneous single access heart pump designed for right heart support to receive FDA approval. The Impella RP device is approved to provide support of the right heart during times of acute failure for certain patients who have received a left ventricle assist device or have suffered heart failure due to AMI, a failed heart transplant, or following open heart surgery. We expect to continue to make additional pre-market approval, or PMA supplement submissions for our Impella portfolio of devices for additional indications.

The Impella SmartAssist platform includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process. The Impella SmartAssist platform currently developed for the Impella CP SmartAssist and Impella 5.5 SmartAssist heart pumps. The Impella SmartAssist platform is also approved under CE Mark in the European Union and other countries that require a CE Mark approval.

Impella Connect is a cloud-based technology that enables secure, cloud-based, remote viewing of the Automated Impella Controller, or AIC, for physicians and hospital staff from anywhere with internet connectivity. The Impella Connect is intended to provide enhanced monitoring capability, reduce setup time and improve ease of use for physicians. We began a controlled roll-out of Impella Connect at certain hospital sites during fiscal 2020 and plan to transition the majority of our significant customers in fiscal 2021.

The Abiomed Breethe OXY-1 System (“OXY-1 System”) is a portable external respiratory assistance device that we acquired as part of the Breethe, Inc. acquisition. The OXY-1 System takes venous blood from the patient, removes carbon dioxide and adds oxygen much like a human lung, and returns the oxygenated blood safely back to the patient. ~~An application for~~In October 2020, the OXY-1 System received a 510(k) clearance ~~was submitted to~~from the FDA for an all-in-one, compact cardiopulmonary bypass system. We plan to have a controlled launch of the Breethe system at a limited number hospitals in ~~January 2020 and we anticipate receiving approval of this submission~~the U.S., with full U.S. commercial availability expected in fiscal ~~2021.~~year 2022.

The Impella ECP pump is designed for blood flow of greater than three liters per minute. It is intended to be delivered on a standard sized catheter and will include an expandable inflow in the left ventricle. We ~~expect to begin~~began patient enrollment ~~later~~ in ~~calendar year 2020, subject to our ability to do so under the circumstances of the ongoing or any future outbreak of COVID-19.~~October 2020. The Impella ECP pump is still in development and has not been approved for commercial use or sale.

The Impella XR Sheath is a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy. The Impella XR Sheath device is still in development and has not been approved for commercial use or sale. We ~~expect to submit~~submitted an application for FDA 510(k) clearance for our Impella 2.5 pump in August 2020 and we also continue to work on development of an Impella XR Sheath on our Impella CP device for an FDA submission in fiscal ~~2021, subject to our ability to do so under the circumstances of the ongoing or any future outbreak of COVID-19.~~2022.

The Impella BTR device is designed to be a percutaneous micro heart pump with integrated motors and sensors. The Impella BTR device is designed to be smaller, provide up to one year of hemodynamic support and is expected to allow for greater than five liters of blood flow per minute. The Impella BTR device also includes a wearable driver designed for hospital discharge. The Impella BTR pump is still in development and has not been approved for commercial use or sale.

Other than the accounting policy changes discussed in “Note 2. Basis of Preparation and Summary of Significant Accounting Policies” to our consolidated financial statements, which is incorporated herein by reference, there have been no significant changes in our critical accounting policies during the three and six months ended ~~June~~September 30, 2020, as compared to the critical accounting policies disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2020.

Results of Operations for the Three and Six Months Ended ~~June~~September 30, 2020 compared with the Three and Six Months Ended ~~June~~September 30, 2019

The following table sets forth certain condensed consolidated statements of operations data for the periods indicated as a percentage of total revenue:

	For the Three Months Ended June 30,								For the Three Months Ended September 30,						For the Six Months Ended September 30,
	2020				2019				2020			2019			2020			2019
Revenue		100.0		%		100.0		%		100.0	%		100.0	%		100.0	%		100.0	%
Costs and expenses as a percentage of total revenue:
Cost of revenue		21.8				17.9				18.5			17.0			19.9			17.4
Research and development		16.0				11.5				14.6			11.7			15.2			11.6
Selling, general and administrative		41.5				41.5				37.7			41.9			39.4			41.7
Total costs and expenses		79.3				70.8				70.8			70.6			74.5			70.7
Income from operations		20.7				29.2				29.2			29.4			25.5			29.3
Other income and income tax provision, net		(6.4	)			(13.6	)			0.5			23.0			3.0			4.4
Net income as a percentage of total revenue		27.0		%		42.8		%		29.7	%		6.4	%		28.5	%		24.9	%

The following table disaggregates the Company’s revenue by products and services:

	For the Three Months Ended June 30,				For the Three Months Ended September 30,				For the Six Months Ended September 30,
		2020		2019		2020		2019		2020		2019
	(in $000's)				(in $000's)				(in $000's)
Impella product revenue	$	155,417	$	199,864	$	199,676	$	196,939	$	355,093	$	396,804
Service and other revenue		9,433		7,802		10,088		8,035		19,521		15,836
Total revenue	$	164,850	$	207,666	$	209,764	$	204,974	$	374,614	$	412,640

The following table disaggregates the Company’s revenue by geographical location:

	For the Three Months Ended June 30,				For the Three Months Ended September 30,				For the Six Months Ended September 30,
		2020		2019		2020		2019		2020		2019
	(in $000's)				(in $000's)				(in $000's)
U.S. revenue	$	134,725	$	175,486	$	172,147	$	172,015	$	306,872	$	347,500
International revenue		30,125		32,180		37,617		32,959		67,742		65,140
Total revenue	$	164,850	$	207,666	$	209,764	$	204,974	$	374,614	$	412,640

Impella product revenue encompasses Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5, Impella RP and Impella AIC product sales and related accessories. Service and other revenue represents revenue earned on service maintenance contracts and preventative maintenance calls.

Total revenue for the three months ended ~~June~~September 30, 2020 ~~decreased~~increased by ~~$42.8~~$4.8 million, or ~~21%~~2%, to ~~$164.9~~$209.8 million from ~~$207.7~~$205.0 million for the three months ended ~~June~~September 30, 2019. Total revenue for the six months ended September 30, 2020 decreased $38.0 million, or 9%, to $374.6 million from $412.6 million for the six months ended September 30, 2019. The ~~decrease~~increase in total revenue ~~was due to lower Impella product revenue from lower utilization of Impella products caused by the impact of COVID-19 reducing hospital procedures~~ in the ~~first~~second quarter of fiscal 2021 ~~primarily in in the U.S~~was driven by both Impella product revenue and ~~Europe.~~our service and other revenue, as further described below.

Impella product revenue for the three months ended ~~June~~September 30, 2020 ~~decreased~~increased by ~~$44.5~~$2.8 million, or ~~22%~~1%, to ~~$155.4~~$199.7 million from ~~$199.9~~$196.9 million for the three months ended ~~June~~September 30, 2019. Impella product revenue for the six months ended September 30, 2020 decreased by $41.7 million, or 11%, to $355.1 million from $396.8 million for the six months ended September 30, 2019. Most of the ~~decrease~~increase in Impella product revenue during the three months ended September 30, 2020 was related to sales growth outside of the U.S. with product sales being relatively flat in the U.S. ~~from the impact of COVID-19.~~ Impella product revenue outside of the U.S. ~~also decreased~~increased primarily due to ~~lower~~higher utilization in ~~Germany.~~ We expect revenue from our Impella devices to increase sequentially each quarter with our recent PMA approvals in the U.S. and our continued controlled launch of Impella devices outside of the U.S., with a primary focus on Germany and Japan.

Impella procedure volumes have varied greatly since the end of March 2020 by geography, and even by hospital, as patients and their physicians ~~managed~~manage through the COVID-19 pandemic. In

Through the last few weeks of the fourth quarter of fiscal 2020, procedure volumes related to our Impella products dropped significantly. Worldwide Impella heart pump revenue was impacted by lower patient utilization in the first quarter of fiscal 2021 due to the impact of the COVID-19 pandemic on elective medical procedures, surgeries and fewer patients seeking treatment at hospitals.

~~During the first~~second quarter of fiscal 2021, patient procedure volume trends ~~began to improve~~have improved gradually ~~over the course of the quarter as~~ both demand for procedures and availability of healthcare resources began to return to more normalized, pre-COVID-19 levels. Our business was most impacted in April, in terms of the decline in patients and revenue from the shelter-in-place restrictions in a majority of countries and limitations on procedures in hospitals.have improved. We experienced sequential quarterly improvement ~~globally in May and June~~during the second quarter of fiscal 2021 as restrictions were somewhat lifted and limitations eased. ~~In the month of June specifically, we experienced year over year growth in both patients and revenue in U.S., Germany, and Japan.~~

While we currently expect to see sequential quarterly improvement in the remainder of fiscal 2021, the COVID-19 pandemic remains fluid and continues to evolve differently across various geographies. We believe we are likely to continue to experience variable impacts on our business based on some of the resurgence that is now occurring in cities across the globe. ~~Given the uncertainty,~~While we cannot reliably estimate the extent to which the COVID-19 pandemic may continue to impact patient utilization and revenues of our products, we expect revenue from our Impella devices to increase sequentially each quarter during fiscal 2021 with our focus on growing key using U.S. sites, our controlled launch of Impella 5.5, primarily in the ~~second quarter of fiscal 2021~~U.S., and ~~beyond.~~our focus on growing our business internationally, with a continued focus on Germany and Japan.

Service and other revenue for the three months ended ~~June~~September 30, 2020 increased by ~~$1.6~~$2.1 million, or ~~21%~~26%, to ~~$9.4~~$10.1 million from ~~$7.8~~$8.0 million for the three months ended ~~June~~September 30, 2019. Service and other revenue for the six months ended September 30, 2020 increased $3.7 million, or 23%, to $19.5 million from $15.8 million for the six months ended September 30, 2019. The increase in service revenue was primarily due to an increase in preventative maintenance service contracts. We have expanded the number of Impella AIC consoles at many of our existing higher volume customer sites and continue to sell additional consoles to new customer sites. We expect revenue growth for service revenue to be consistent with recent history as most of these using sites in the U.S. have service contracts that normally have three-year terms.

Cost of revenue for the three months ended ~~June~~September 30, 2020 ~~decreased~~increased by ~~$1.1~~$3.8 million, or 3%11%, to ~~$36.0~~$38.7 million from ~~$37.1~~$34.9 million for the three months ended ~~June~~September 30, 2019. Gross margin was ~~78.2%~~81.5% for the three months ended ~~June~~September 30, 2020 and ~~82.1%~~83.0% for the three months ended ~~June~~September 30, 2019.

Cost of revenue for the six months ended September 30, 2020 increased by $2.8 million, or 4%, to $74.7 million from $71.9 million for the six months ended September 30, 2019. Gross margin was 80.1% for the six months ended September 30, 2020 and 82.6% for the six months ended September 30, 2019.

The ~~decrease~~increase in cost of product revenue and decrease in gross margin during the three and six months ended September 30, 2020 was related to lower ~~demand for~~production volume of our Impella devices and ~~lower production volume and costs for our Impella devices. The decrease in gross margin was primarily due to lower production in the three months ended June 30, 2020 as well as~~ costs associated with our initial launch of ~~Impella 5.5,~~our Impella CP SmartAssist and Impella ~~Connect.~~Connect products.

We expect that our ongoing investment in manufacturing capacity and the expansion of our Impella CP SmartAssist and Impella Connect platform may decrease gross margin slightly in the near future.

Research and development expenses for the three months ended ~~June~~September 30, 2020 increased by ~~$2.6~~$6.5 million, or ~~11%~~27%, to ~~$26.4~~$30.5 million from ~~$23.8~~$24.0 million for three months ended ~~June~~September 30, 2019.Research and development expense for the six months ended September 30, 2020 increased $9.1 million, or 19%, to $56.9 million from $47.8 million for the six months ended September 30, 2019. The increase in research and development expenses was primarily due to product development initiatives relating to our existing and pipeline products, the ~~Breethe~~development of the OXY-1 ~~system ECMO technology~~System, Impella XR Sheath™ and Impella ECP™ devices, the expansion of our engineering organization, investment in our clinical trials and studies, most notably the DTU-STEMI study and our continued focus on clinical and quality initiatives for our Impella products ~~partially offset by decreases in clinical spending related to temporary~~ ~~delays in clinical trial enrollment due to the COVID-19 pandemic.~~.

We expect research and development expenses to continue to increase as we continue to increase engineering, product development and clinical spending related to our ~~engineering~~ initiatives to improve our existing products and develop new technologies and conduct clinical studies. ~~In the first quarter of fiscal 2021, we started to resume patient enrollment in clinical trials that were temporarily paused at the end of the fourth quarter of fiscal 2020.~~ Research and development expenses can fluctuate with project timing.

Selling, general and administrative expenses for the three months ended ~~June~~September 30, 2020 decreased by ~~$17.7~~$6.8 million, or ~~21%~~8%, to ~~$68.4~~$79.2 million from ~~$86.1~~$86.0 million for the three months ended ~~June~~September 30, 2019. Selling, general, and administrative expenses for the six months ended September 30, 2020 decreased $24.4 million, or 14%, to $147.6 million from $172.0 million for the six months ended September 30, 2019. The decrease in selling, general and administrative expenses was primarily due to the proactive cost actions to mitigate the business impact of COVID-19 on our financial operations, including reducing discretionary spending primarily related to travel and marketing expenses, decreases in hiring, eliminating certain non-critical consultants and ~~contractors, and temporary salary reductions for certain members of management.~~contractors. In addition, stock compensation expense was lower due to a lower number of restricted stock units granted and earned.

Despite the ongoing challenges posed by COVID-19, we expect to continue to invest on sales and marketing activities, with a particular focus on in training and education initiatives to drive utilization of our Impella devices and recovery awareness for acute heart failure patients. We also expect to continue to incur legal expenses for the foreseeable future related to ongoing patent litigation, securities class action litigation and other legal matters discussed in “Note 14. Commitment and Contingencies” to our consolidated financial statements. For the impact of COVID-19 on our business, see “COVID-19 Pandemic.”

Operating income for the three months ended ~~June~~September 30, 2020 ~~decreased~~increased by ~~$26.6~~$1.1 million, to ~~$34.1~~$61.3 million, compared to ~~$60.7~~$60.2 million for the three months ended ~~June~~September 30, 2019. Operating margin was ~~20.7% for the three months ended June 30, 2020 compared to~~ 29.2% for the three months ended ~~June~~September 30, ~~2019. The decrease in operating margin was primarily due~~2020 compared to ~~the lower Impella product revenue and gross margin~~29.4% for the three months ended ~~June~~September 30, ~~2020. For~~2019. Operating income for the ~~impact of COVID-19 on our business, see “COVID-19 Pandemic.”~~six months ended September 30, 2020 decreased by $25.5 million, to $95.4 million, compared to $120.9 million for the six months ended September 30, 2019. Operating margin was 25.5% for the six months ended September 30, 2020 compared to 29.3% for the six months ended September 30, 2019.

Other income (expense), net ~~decreased~~increased by ~~$15.4~~$54.4 million, to ~~$27.0~~other income of $11.6 million for three months ended September 30, 2020, compared to other expense of $42.8 million for three months ended ~~June~~September 30, 2019. Other income (expense), net increased by $39.0 million, to other income of $38.6 million for the six months ended September 30, 2020, compared to ~~$42.4~~other expense of $0.4 million for ~~three~~the six months ended ~~June~~September 30, ~~2019.~~2019. This ~~decrease~~increase was primarily due to ~~the recognition~~a gain of ~~a $23.8~~$10.8 million ~~gain~~and $34.7 million from our investment in Shockwave Medical during the three and six months ended ~~June~~September 30, 2020, respectively, compared to a ~~$39.7~~loss of $45.6 million ~~gain~~and $5.9 million on the same investment for the three and six months ended ~~June~~September 30, ~~2019.~~2019, respectively.

Our income tax provision was ~~$16.5~~$10.7 million and ~~$14.2~~$4.3 million for the three months ended ~~June~~September 30, 2020 and 2019, respectively, and our income tax provision was $27.2 million and $18.5 million for the six months ended September 30, 2020 and 2019, respectively. Our effective income tax rate was ~~27.0%~~14.7% and ~~13.8%~~24.7% for the three months ended ~~June~~September 30, 2020 and 2019, respectively, and 20.3% and 15.4% for the six months ended September 30, 2020 and 2019, respectively. The ~~increase~~decrease in the effective income tax rate was due primarily to ~~lower~~higher excess tax benefits recognized associated with stock-based awards of ~~$0.5~~$7.9 million and ~~$12.8~~$0.5 million as an income tax benefit for three months ended ~~June~~September 30, 2020 and 2019 ~~respectively.~~respectively, and of $8.5 million and $13.3 million for the six months ended September 30, 2020 and 2019. These recognized excess tax benefits resulted from restricted stock units that vested or stock options that were exercised during the three months ended ~~June~~September 30, 2020 and 2019, respectively.

For the three months ended ~~June~~September 30, 2020, net income was ~~$44.6~~$62.2 million, or ~~$0.99~~$1.38 per basic share and ~~$0.98~~$1.36 per diluted share, compared to ~~$88.9~~$13.1 million, or ~~$1.97~~$0.29 per basic share and ~~$1.93~~$0.28 per diluted share, for three months ended ~~June~~September 30, 2019.For the six months ended September 30, 2020, net income was $106.8 million, or $2.37 per basic share and $2.34 per diluted share, compared to $102.0 million, or $2.25 per basic share and $2.22 per diluted share for the six months ended September 30, 2019.

Net income for the three months ended ~~June~~September 30, 2020 included excess tax benefits related to stock-based awards of ~~$0.5~~$7.9 million, or ~~$0.01~~$0.18 per basic share and ~~$0.01~~$0.17 per diluted share, and a ~~$17.9~~total $8.2 million ~~unrealized~~ gain, net of tax, or ~~$0.39~~$0.18 per basic and diluted share, related to our investment in Shockwave Medical. Net income for the three months ended ~~June~~September 30, 2019 included excess

tax benefits related to stock-based awards of $0.5 million, or $0.01 per basic and diluted share, and a $34.5 million unrealized loss, net of tax, or $0.76 per basic share and $0.75 per diluted share, related to our investment in Shockwave Medical.

Net income for the six months ended September 30, 2020 included excess tax benefits related to stock-based awards of $8.5 million, or $0.19 per basic and diluted share, and a $26.1 million gain, net of tax, or $0.58 per basic and $0.57 per diluted share, related to our investment in Shockwave Medical. Net income for the six months ended September 30, 2019 included excess tax benefits related to stock-based awards of ~~$12.8~~$13.3 million, or ~~$0.28~~$0.29 per basic ~~share~~ and ~~$0.28 per~~ diluted share, and a ~~$30.0~~$4.5 million unrealized ~~gain,~~loss, net of tax, or ~~$0.65~~$0.10 per basic and diluted share, related to our investment in Shockwave Medical.

At ~~June~~September 30, 2020, our total cash, cash equivalents and marketable securities totaled ~~$597.0~~$735.7 million, ~~a decrease~~an increase of ~~$53.9~~$84.8 million compared to $650.9 million at March 31, 2020. The ~~decrease~~increase in our cash, cash equivalents and marketable securities during the ~~three~~six months ended ~~June~~September 30, 2020 was primarily due to ~~the acquisition of Breethe, Inc., payment of~~cash flows provided by operating activities offset by cash used to fund our annual bonuses and proceeds from the sale of shares in Shockwave Medical. These amounts were offset by taxes paid related to net settlement of vesting of stock awards during the period and purchases of property and ~~equipment, partially offset by cash flows provided by operating activities.~~equipment.

	For the Three Months Ended June 30,						For the Six Months Ended September 30,
	2020			2019			2020			2019
Net cash provided by operating activities	$	31,759		$	64,628		$	108,968		$	138,887
Net cash provided by (used for) by investing activities		13,756			(45,937	)
Net cash used for investing activities								(81,314	)		(38,011	)
Net cash used for financing activities		(20,156	)		(39,276	)		(14,711	)		(71,005	)
Effect of exchange rate changes on cash		(2,873	)		612			(3,043	)		(613	)
Net decrease in cash and cash equivalents	$	22,486		$	(19,973	)
Net increase in cash and cash equivalents							$	9,900		$	29,258

For the ~~three~~six months ended ~~June~~September 30, 2020, cash provided by operating activities consisted of net income of ~~$44.6~~$106.8 million, adjustments for non-cash items of ~~$7.2~~$19.7 million and cash used in working capital of ~~$20.0~~$17.5 million. As discussed above, the change in net income was primarily due to modest increases in Impella revenue, lower ~~excess tax benefits~~selling, general and ~~lower revenue from decreased utilization of our Impella devices~~administrative expenses to reduced discretionary spending and ~~partially offset by our gain~~hiring and gains from our investment in Shockwave ~~Medical.~~Medical, partially offset by increases in research and development expenses due to product development and clinical initiatives relating to our existing and pipeline products and lower excess tax benefits. Adjustments for non-cash items consisted primarily of ~~$9.3~~$20.9 million of stock-based compensation expense, ~~$12.9~~$14.2 million in deferred tax provision, ~~$5.5~~$11.1 million of depreciation and amortization expense, ~~$1.7~~$3.1 million in inventory and other write-downs, and ~~$0.1~~$0.5 million in accretion on marketable securities. The change in cash from working capital included a ~~$3.0~~$4.8 million decrease in accounts receivable due to timing of collections, a ~~$0.2~~$6.1 million ~~increase~~decrease in inventory due to ~~support demand for our Impella devices,~~lower production volumes, a ~~$24.0~~$32.1 million decrease in accounts payable and accrued expenses primarily due to payment of annual bonuses during the quarter ended ~~June~~September 30, 2020, and a ~~$0.7~~$2.0 million increase in deferred revenue.

For the ~~three~~six months ended ~~June~~September 30, 2019, cash provided by operating activities consisted of net income of ~~$88.9~~$102.0 million, adjustments for non-cash items of ~~$10.1~~$54.5 million and cash used in working capital of ~~$14.2~~$17.6 million. As discussed above, the change in net income was primarily due to lower excess tax benefits partially offset by higher revenue from increased utilization of our Impella devices and ~~our gain from~~an unrealized loss related to our investment in Shockwave Medical. Adjustments for non-cash items consisted primarily of ~~$13.1~~$26.4 million

of stock-based compensation expense, ~~$10.8~~$10.2 million in deferred tax provision, ~~$4.4~~$9.1 million of depreciation and amortization expense, ~~$1.3~~$2.3 million in accretion on marketable securities, and $2.2 million in inventory and other ~~write-downs, and $1.3 million in accretion on marketable securities.~~write-downs. The change in cash from working capital included a ~~$4.8 million decrease in accounts receivable due to timing of collections, a $7.2~~$12.2 million increase in inventory to support demand for our Impella devices, $3.8 million increase in accounts receivable due to timing of collections, a ~~$8.1~~$3.0 million increase in deferred revenue, and a $0.5 million decrease in accounts payable and accrued ~~expenses primarily due to payment of annual bonuses during the quarter ended June 30, 2019, and a $0.2 million decrease in deferred revenue.~~expenses.

For the ~~three~~six months ended ~~June~~September 30, 2020, net cash ~~provided by~~used for investing activities primarily consisted of ~~$77.7~~$74.4 million in ~~proceeds~~purchases from the sale of marketable securities (net of ~~purchases)~~maturities), ~~partially offset by $10.0~~$52.2 million in net cash for our acquisition of Breethe and $19.6 million used in the purchase of property and equipment primarily related to continued expansion of manufacturing capacity, office space and research development facilities in Danvers and Aachen, Germany. We ~~used $51.9 million in net cash for our acquisition of Breethe in April 2020.~~also ~~We also~~ made an additional ~~$2.0~~$3.1 million investment in a private medical technology ~~company~~companies during fiscal 2021. These amounts were partially offset by $67.9 million in proceeds from the sale of Shockwave Medical securities.

For the ~~three~~six months ended ~~June~~September 30, 2019, net cash used for in investing activities primarily consisted of ~~$30.9~~$5.6 million in maturities (net of purchases) of marketable securities ~~partially offset by $12.3~~and $24.6 million used in the purchase of property and equipment primarily

related to continued expansion of manufacturing capacity, office space and research development facilities in Danvers and Aachen, Germany. We ~~also made~~invested an additional ~~$2.8~~$7.8 million ~~investment~~ in a private medical technology ~~company~~companies during fiscal ~~2020.~~2019.

Capital expenditures for fiscal 2021 are estimated to range from ~~$30~~$30.0 million to ~~$50~~$50.0 million, including additional capital expenditures for manufacturing capacity expansions in our Danvers and Aachen facilities, additional office space, building and leasehold improvements and information systems development projects.

For the ~~three~~six months ended ~~June~~September 30, 2020, net cash used for financing activities included $11.3~~$11.3~~ million for the repurchase of our common stock and ~~$9.9~~ $10.9 million in payments in lieu of issuance of common stock for payroll withholding taxes upon vesting of certain equity awards. ~~This amount was~~These amounts were offset by ~~$1.0~~$5.6 million in proceeds from the exercise of stock ~~options.~~ options and $2.0 million in proceeds from the issuance of stock under the employee stock purchase plan.

For the ~~three~~six months ended ~~June~~September 30, 2019, net cash used for financing activities included ~~$40.5~~$41.2 million in payments in lieu of issuance of common stock for payroll withholding taxes upon vesting of certain equity ~~awards. This amount was~~awards and $34.9 million used in the repurchase of our common stock. These amounts were offset by ~~$1.3~~$2.7 million in proceeds from the exercise of stock ~~options.~~ options and $2.4 million in proceeds from the issuance of stock under the employee stock purchase plan.

Our sources of cash liquidity are primarily from existing cash and cash equivalents, marketable securities and cash flows from operations. ~~At June~~On September 30, 2020, our total cash, cash equivalents, and short and long-term marketable securities totaled ~~$597.0~~$735.7 million, a decrease of ~~$53.9~~$84.8 million compared to $650.9 million at March 31, 2020. Marketable securities at ~~June~~September 30, 2020 consisted of ~~$382.2~~$533.5 million held in funds that invest in U.S. Treasury securities, government-backed securities, corporate debt securities and commercial paper. We generated operating cash flows of ~~$31.8~~$109.0 million and ~~$64.6~~$138.9 million for ~~three~~the six months ended ~~June~~September 30, 2020 and 2019, respectively. At ~~June~~September 30, 2020, we had no debt outstanding. We believe that our sources of liquidity are sufficient to fund the current requirements of working capital, capital expenditures, and other financial commitments for at least the next twelve months.

Our primary liquidity requirements are to fund the following: expansion of our commercial and operational infrastructures; expansion of our manufacturing capacity and office space; the procurement and production of inventory to meet customer demand for our Impella devices; ~~creation~~funding of new product and business development initiatives, such as the recent acquisition of Breethe; ongoing commercial launch in Japan and expansion into potential new markets; ~~expansion of the utilization of Impella Connect;~~ increased clinical spending; legal expenses related to ongoing patent litigation and other legal matters; stock repurchases and payments in lieu of issuance of common stock for payroll withholding taxes upon vesting of certain equity awards and provide for general working capital needs. To date, we have primarily funded our operations through product sales and the sale of equity securities.

Our liquidity is influenced by our ability to sell our products in a competitive industry and our customers’ ability to pay for our products. Factors that may affect liquidity primarily include our ability to penetrate the market for our products, our ability to maintain or reduce the length of the selling cycle for our products, our capital expenditures, and our ability to collect cash from customers after our products are sold. We continue to review our short-term and long-term cash needs on a regular basis.

As discussed in “COVID-19 Pandemic,” we have taken proactive actions to mitigate the business impact of COVID-19 on our financial operations. While we currently expect to see sequential quarterly improvement in the remainder of fiscal 2021, the COVID-19 pandemic remains fluid and continues to evolve differently across various geographies. We believe we are likely to continue to experience variable impacts on our business based on some of the resurgence that occurring in cities across the globe. Given the uncertainty, we cannot reliably estimate the extent to which the COVID-19 pandemic may continue to impact patient utilization and revenues of our products in the second quarter of fiscal 2021 and beyond.

We had no off-balance sheet arrangements or guarantees of third-party obligations during the periods presented. An “off-balance sheet arrangement” generally entails a transaction, agreement or other contractual arrangement to which an entity unconsolidated with us, is a party under which we have any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

We have various contractual obligations, which are recorded as liabilities in our consolidated condensed financial statements. Other items are not recognized as liabilities in our consolidated condensed financial statements but are required to be disclosed. There have been no material changes, outside of the ordinary course of business, to our contractual obligations as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2020.

There have been no material changes to our quantitative and qualitative disclosures about market risk as compared to the quantitative and qualitative disclosures about market risk described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2020.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of ~~June~~September 30, 2020. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of ~~June~~September 30, 2020, these disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us, including our consolidated subsidiaries, in reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

During the ~~first~~second quarter of our fiscal year ending March 31, 2021, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As a result of the COVID-19 pandemic, beginning in mid-March 2020 and through the first quarter of fiscal 2021, certain of our employees began working remotely. As a result of these changes to the working environment weWe have not ~~identified~~experienced any material ~~changes in~~impact to our internal control over financial ~~reporting.~~reporting despite the fact that certain of our employees have been working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the potential impact of COVID-19 ~~situation~~on our internal controls to ~~determine any potential impacts~~minimize the impact on ~~the~~their design and operating ~~effectiveness of our internal control over financial reporting.~~effectiveness.

We are from time to time involved in various legal actions, the outcomes of which are not within our complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, which, if granted, would require significant expenditures and could impair our business and results of operations. Material legal proceedings are discussed in “Note 14. Commitments and Contingencies” to our condensed consolidated financial statements and such information is incorporated herein by reference.

Investing in our common stock involves a high degree of risk. In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2020, which could materially affect our business, financial condition or future results. As of the date of this Report there has been no material change in any of the risk factors described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2020.

On November 5, 2020, the Company made a one-time grant of performance-based restricted stock units (“PSUs”) to the following named executive officers (“NEOs”) listed in its definitive proxy statement on Schedule 14A filed with the SEC on June 30, 2020: Chairman, President and Chief Executive Officer Michael R. Minogue; Vice President and Chief Financial Officer Todd A. Trapp; Vice President and Chief Commercial Officer Andrew J. Greenfield; and Senior Vice President and Chief Operating Officer David M. Weber. The Compensation Committee of the Board of Directors determined to grant these awards in order to align management around a strategic COVID-19 recovery plan developed to create value for shareholders. The Company also considered the performance of its NEOs during the COVID-19 pandemic to date, market data and the input of the Committee’s independent compensation consultant. The target number of PSUs granted was 12,000 for Mr. Minogue and 4,500 for each of the other NEOs. The PSUs may be earned based on certain performance milestones after a one-year performance period, and, to the extent earned, will time-vest 50% shortly after the end of the one-year performance period and 50% on the second anniversary of the grant date, in each case, subject to the NEO’s continued employment on the vesting date and settlement date. Payouts under the PSUs are capped at 200% of target, and are based on a revenue growth metric, representing 30% weight of total payout, and certain other quantitative business metrics focusing on new product development, human capital, and operations during the pandemic, representing 70% weight of total payout. Additionally, in recognition of his focused leadership of the Company during the pandemic, Mr. Minogue’s earned PSU amount may be multiplied by an additional 125% if the Company achieves certain other strategic business metrics not included in the other NEOs’ PSU grants, for a potential maximum payout of 250% of target.

Exhibit No.

Description

Filed with
This
Form 10-Q

Incorporated by Reference

Description

Filed with
This
Form 10-Q

Incorporated by Reference

Form

Filing Date

Exhibit No.

Form

Filing Date

Exhibit No.

3.1

Restated Certificate of Incorporation

S-3

September 29, 1997

3.1

Restated Certificate of Incorporation

S-3

September 29, 1997

3.1

3.2

Amended & Restated By-Laws, as Amended and Restated February 4, 2020

10-K

May 21, 2020
(File No. 001-09585)

3.2

Amended & Restated By-Laws, as Amended and Restated February 4, 2020

10-K

May 21, 2020
(File No. 001-09585)

3.2

3.3

Amendment to the Company’s Restated Certificate of Incorporation to increase the authorized shares of common stock from 25,000,000 to 100,000,000

8-K

March 21, 2007
(File No. 001-09585)

3.4

Amendment to the Company’s Restated Certificate of Incorporation to increase the authorized shares of common stock from 25,000,000 to 100,000,000

8-K

March 21, 2007
(File No. 001-09585)

3.4

10.1

Form of Executive Officer Time-Based RSU Agreement under the Second Amended and Restated 2015 Omnibus Incentive Plan

10.2

Form of Executive Officer Time-Based Stock Option Agreement under the Second Amended and Restated 2015 Omnibus Incentive Plan

10.3

Form of Executive Officer Performance-Based PSU Agreement under the Second Amended and Restated 2015 Omnibus Incentive Plan

31.1

Rule 13a—14(a)/15d—14(a) certification of principal executive officer

31.2

Rule 13a—14(a)/15d—14(a) certification of principal accounting officer

32.1

Section 1350 certification

101

The following financial information from the ABIOMED, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in inline Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets as of June 30, 2020 and March 31, 2020; (ii) Condensed Consolidated Statements of Operations for the three months ended June 30, 2020 and 2019; (iii) Condensed Consolidated Statements of Comprehensive Income for the three months ended June 30, 2020 and 2019; (iv) Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2020 and 2019; and (v) Notes to Condensed Consolidated Financial Statements.

The following financial information from the ABIOMED, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in inline Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets as of and March 31, 2020; (ii) Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2020 and 2019; (iii) Condensed Consolidated Statements of Comprehensive Income for the three and six months ended September 30, 2020 and 2019; (iv) Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2020 and 2019; and (v) Notes to Condensed Consolidated Financial Statements.

104

Cover page from the ABIOMED, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in iXBRL and contained in Exhibit 101

Cover page from the ABIOMED, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 formatted in iXBRL and contained in Exhibit 101

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

Delaware		04-2743260
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, $0.01 par value	ABMD	The NASDAQ Stock Market LLC

PART I - FINANCIAL INFORMATION:			Page

Item 1.	Condensed Consolidated Financial Statements (unaudited)	3

	Condensed Consolidated Balance Sheets as of ~~June~~September 30, 2020 and March 31, 2020	3

	Condensed Consolidated Statements of Operations for the three and six months ended ~~June~~September 30, 2020 and 2019	4

	Condensed Consolidated Statements of Comprehensive Income for the three and six months ended ~~June~~September 30, 2020 and 2019	5

	Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended ~~June~~September 30, 2020 and 2019	6

	Condensed Consolidated Statements of Cash Flows for the ~~three~~six months ended ~~June~~September 30, 2020 and 2019	7

	Notes to Condensed Consolidated Financial Statements (unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2627

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36

Item 4.	Controls and Procedures	36

PART II - OTHER INFORMATION:

Item 1.	Legal Proceedings	37

Item 1A.	Risk Factors	37

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37

Item 3.	Defaults Upon Senior Securities	37

Item 4.	Mine Safety Disclosures	37

Item 5.	Other Information	37

Item 6.	Exhibits	38

Signatures		39


	Effective Date	Maturity	Fixed Rate	Aggregate Notional Amount (in $000's)
Pay EUR	October 15,	October 15,	2.75%		EUR 85,000
Receive U.S.$	2019	2024	4.64%		USD 93,457


Risk-free interest rate		~~0.2~~	%0.2%
Expected volatility		~~35.5~~	%35.5%
Dividend yield		—
Remaining performance period (years)	1.9 - 2.9
Estimated fair value per share	$347.05 - $349.28
Target performance (number of shares)		30,781

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

	Three Months Ended June 30, 2019
	Foreign Currency Translation Gains (Losses)			Unrealized Gains on Investments		Gains (Losses) on Derivative Instruments		Total
Balance, April 1, 2019		(15,028	)		339		—		(14,689	)
Other comprehensive income (loss)		2,334			600		—		2,934
Balance, June 30, 2020		(12,694	)		939		—		(11,755	)

Period	Total Number of Shares Purchased (1)		Average Price Paid per Share (1)		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)		Approximate Dollar Value Maximum of Shares that May Yet Be Purchased Under the Plans or Programs (in $000's) (2)
April 1- 30, 2020		48,448		159.02		48,448		107,415
May 1-31, 2020		19,201		187.79		19,201		103,809
June 1-30, 2020		—		—		—		103,809	��
Total		67,649	$	167.19		67,649	$	103,809

		ABIOMED, Inc.

Date: ~~August~~November 6, 2020		/s/ TODD A. TRAPP
		Todd A. Trapp
		Vice President and Chief Financial Officer
		(Authorized Signatory)